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CHAPTER 1 
GENERAL INTRODUCTION 
 
 
Embryology and anatomy of the human placenta 
The human placenta is divided into 20 to 40 independent functional units, called 
cotyledons. An isolated cotyledon is an ideal target for studies on foetoplacental 
vascular, and transplacental transport function. For a better understanding of these 
placental units, and the experimental methods used in the studies described, this first 
paragraph deals with the development and anatomy of the human placenta.  
About three days after ovulation and fertilization, the zygote reaches the uterine cavity 
as the so-called morula. In the uterine cavity the morula develops into a blastocyst; a 
cavity with fluid inside, surrounded by cells called blastomeres. In one pole of the 
blastocyst, a compact cell mass comes into existence – the inner cell mass - which is 
designed to produce the embryo. The outer cell mass is destined to become non-
embryonic cells, the trophoblasts. The blastocyst causes an irritative reaction in the 
maternal decidua to the effect that it can fully nidate into the maternal mucous tissue. 
It is surprising that the maternal body does not reject the embryonic tissue. This is 
probably due to the fact that the extravillous trophoblastic cells, which are the only 
cells in direct contact with maternal tissue, produce HLA antibodies, which prevent 
such rejection [1]. Morphologically, the trophoblasts are either cellular or syncythial, 
and may appear as uninuclear (cytotrophoblasts) or multinuclear giant cells 
(syncytiotrophoblasts). The cytotrophoblast is a cellular progenitor of the 
syncytiotrophoblast.    
Soon after nidation, the blastocysts and trophoblasts grow and expand rapidly. One 
pole of this mass extends towards the uterine cavity; the other remains buried in the 
decidua. As the embryo enlarges, more decidua basalis is invaded and the walls of the 
superficial decidual capillaries are eroded. As a consequence, maternal blood leaks out 
into lacunae. From throphoblasts primitive villi develop, which traverse these lacunae. 
Most villi disappear again, except those located at the placental pole. Cytotrophoblastic 
cells invade the spiral arteries inducing degenerative changes in these vessels, causing 
the vascular smooth muscle in these vessels to become non-recognizable. The 
cytotrophoblastic cells bathe in the maternal blood. Primary villi can be first 
distinguished in the human placenta on about the 12th day after fertilization. In 
secondary villi the trophoblast column is invaded by mesenchymal cells. From these 
mesenchymal cells angiogenesis occurs to form the foetoplacental vascular bed. The 
resulting villi are called tertiary villi. On about the 17th day the foetal vessels are 
functional and the first preliminary placental circulation is established. A number of villi 
extend to the decidua to serve as anchoring villi, but most villi project into the 
intervillous space without reaching the decidua. As the placenta matures, the early 
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stem villi branch and subdivide into increasingly small villi. These terminal villi are the 
most important functional unit in a placenta. Each main stem villus and its finer 
subdivisions form a placental cotyledon, each with its own branch of the chorionic 
artery and vein (figure 1).  
A full-grown placenta is a discoid flat organ with a diameter of 15 – 20 cm, a thickness 
of 2.0 – 3.5 cm and an average weight of 450 – 600 gr. The human placenta is, like 
that of the guinea pig, of the haemochorioendothelial type; at all sites of direct cell-to-
cell contact, maternal tissues (decidua and blood) are juxtaposed to extra-embryonic 
cells (syncytiotrophoblasts) and not to embryonic cells. The apical (microvillous) 
membrane of the syncytiotrophoblast faces towards the maternal tissues, whereas the 
basolateral membrane is directed towards the foetal tissues. 
 
 
Foetoplacental circulation 
Deoxygenated blood flows from the foetus towards the placenta through two umbilical 
arteries. At the chorionic plate they branch into the chorionic arteries. After three to 
four divisions the chorionic arteries perforate the chorionic plate and are now called 
truncal arteries. Each truncal artery supplies one cotyledon. From this division on there 
is a decrease of smooth muscle cells in the vessel wall. A further division leads to 
villous vessels, finally resulting in the tertiary villous network. Oxygenated blood returns 
from the placenta to the foetus through one umbilical vein.  
 
 
Maternal placental circulation 
Maternal blood enters through the basal plate and reaches the chorionic plate driven by 
the maternal blood pressure. After bathing the microvillous surface of the chorionic villi 
in the intervillous space, the blood returns to the uterine veins. Where the uterine spiral 
arteries are perpendicular to the uterine wall, the veins are parallel. This means that 
during a uterine contraction the veins are closed and no maternal blood can disappear 
from the intervillous space, and so it creates an optimal environment for continuous 
maternal-to-foetal and vice versa exchange of gas and (micro)nutrients.  
 
 
Foetoplacental vascular function 
Because the foetoplacental vascular system lacks autonomic innervation [2], its 
vascular function depends entirely on biophysical, and humoral/paracrine/autocrine 
stimuli. In the foetoplacental vascular bed a variety of vasoactive mediators and their 
effects have been recognized (table 1). Most of these effects are identical in the  
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Figure 1 
Anatomical presentation of a human placental cotyledon  
From: Human Microscopic Anatomy 
©Prof R.J. Krstic / Springer-Verlag GmbH Berlin Heidelberg 1991 
A = umbilical artery, V = umbilical vein, UC = umbilical cord,  
PV = placental villus, Sy = syncytiotrophoblast, Cy = cytotrophoblast, 
DC = decidual cell, IS = intervillous space, CP = chorionic plate,  
DB = decidua basalis, FP = foetal placenta, MP = maternal placenta,  
UA = uteroplacental arteries, MV = maternal veins, UG = uterine glands 
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foetoplacental circulation and other vascular beds. Nitric oxide (NO), endothelium 
derived hyperpolarizing factor (EDHF), and prostacyclin (PGI2) seem to be the most 
relevant endothelium derived relaxing factors (EDRF). Endothelin and thromboxane A2 
(TXA) are common vasoconstrictors. Although bradykinin, serotonin, and hypoxia result 
in vasoconstriction in the foetoplacental vascular bed, these agents induce vasodilation 
in other vascular beds.  
 
 
Figure 2 
Schematic presentation of the NO pathway in the foetoplacental vascular bed, and the 
effect of L-NAME on this pathway. VSMC = vascular smooth muscle cell. 
 
 
In the past decade, NO has been identified as an important endogenous regulator of 
vascular tone. Endothelial release of NO causes a significant dilation of the 
foetoplacental vascular bed in the placental circulation, as well [3;4]. The endothelial 
NO-pathway is schematically presented in figure 2. 
Apart from the NO pathway, EDHF seems to be an important factor for the 
maintenance of baseline vascular tone. Different mediators are mentioned to act as an 
EDHF [5-8]. Although the identity of EDHF has not fully been elucidated, the activation 
of potassium channels is a final common pathway. Smooth muscle potassium channels, 
which in open state cause a shift of potassium out of the cell, play a major role in the 
hyperpolarization of the vascular smooth muscle cell wall. This triggers the closure of 
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voltage-dependent calcium channels, resulting in a lower level of cytosolic calcium and 
subsequent relaxation of the vascular smooth muscle cell (figure 3).  
 
 
 
 
Figure 3 
Schematic presentation of the EDHF pathway in the foetoplacental vascular bed, and 
the influence of potassium channel blockers on this pathway in the vascular smooth 
muscle (left), and endothelial cell (right). Em = membrane potential. 
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A third EDRF, which is involved in the maintenance of baseline foetoplacental vascular 
tone, is the prostanoid PGI2. PGI2 acts as a vasodilator in the foetoplacental vascular 
bed [9;10], and has a role in the maintenance of baseline vascular tone [11;12]. It has 
a close relationship with the prostanoid TXA, because the enzyme cycloogygenase 
(COX) is involved in the biosynthesis of both prostanoids (figure 4), but TXA acts as a 
vasoconstrictor [9;13].  
 
 
Figure 4 
Schematic reproduction of the  COX pathway in the foetoplacental vascular bed, and 
the point of application of indomethacin on this pathway  
 
 
As the foetoplacental vascular bed is characterized by low resistance, an impaired 
availability of vasoactive mediators might result in a disturbed foetoplacental vascular 
function, and subsequent disturbed foetal development. 
 
Foetoplacental vascular function in diabetes mellitus 
Despite excellent metabolic control of women with Type 1 diabetes mellitus even long 
before conception, obstetrical complications, such as perinatal mortality, remain more 
prevalent in diabetic mothers [14, 15]. Unfortunatly, for most complications it remains 
unknown why these complications are more prevalent in diabetic mothers. Next to 
intrauterine periods of hypo- or hyperglycemia, a disturbance in the foetoplacental 
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circulation may contribute to this increased complication rate. Diabetes is known to 
have a functional effect on both macro- and microcirculation. Especially endothelial 
dysfunction is a common finding in diabetes [16-19]. Although exposure of the 
placenta to the diabetic environment is limited to the duration of pregnancy, previous 
experiments have shown that this is long enough to develop functional changes in 
vasculature [20].  
The expression of endothelial NO-synthase (eNOS) is increased in the human placenta 
in diabetes [21]. This suggests an increased placental production of NO. The vascular 
reactivity to the NO-donor glyceryl trinitrate, however, is decreased when compared to 
healthy controls [22]. This may be due to reactive oxygen species (ROS), which 
inactivate NO by formation of peroxynitrite. Indeed, there is evidence for an increased 
formation of peroxynitrite in the foetoplacental circulation [23]. Additionally, 
hyperglycaemia has been reported to impair endothelium-dependent vasodilation [24], 
in particular by reducing the bioavailability of NO. The foetoplacental circulation of 
diabetic patients is not only exposed to high glucose concentrations, but also to high 
insulin concentrations, as hyperglycaemia will elicit insulin release from the foetal 
pancreas. Interestingly, high insulin levels have been reported to increase the 
endothelial release of NO [25]. Hyperglycaemia and hyperinsulinaemia occur 
simultaneously in the foetoplacental circulation, and therefore the activity of the NO 
pathway is thought to be different in this circulation from women with diabetes. 
Additionally, recent research points towards an impaired release of EDHF in diabetes 
[26;27]. The baseline release of EDHF may be impaired in the foetoplacental circulation 
as well, and therefore contribute to the aetiology of perinatal complications in diabetes.  
Finally, in diabetes a disturbed TXA to PGI2 ratio has been shown in the foetoplacental 
and other vascular beds [28-30]. This is more profound in the foetoplacental vascular 
bed, than in the umbilical arteries [31]. The foetoplacental response to PGI2 as well as 
to the TXA-analogue U-46619 is attenuated in diabetes [22]. Moreover, the affinity of 
TXA for its receptor is reduced in placentae from diabetic women  [20]. As such, the 
functions of PGI2 as well as TXA seem to be impaired in diabetes. Therefore, the 
underlying defect may be an impairment of the function of the enzyme COX in this 
particular vascular bed in diabetes. To our knowledge no data on the contribution of 
COX to baseline vascular tone in the foetoplacental vascular bed in diabetes are 
available. 
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Table 1 
Vasoactive mediators / stimuli and their effects in the human placental vascular bed 
from uncomplicated nondiabetic pregnancies. 
Mediator Technique  Effect Ref. 
acetylcholine cotyl. perf. none [32;33] 
 patch clamp hyperpolarization of VSMC [34] 
adenosine / ATP cotyl. perf. foetoplacental vasodilation [35] 
angiotensin II  myography foetoplacental vasoconstriction [36] 
 cotyl. perf. foetoplacental vasoconstriction [35;37] 
bradykinin myography constriction of foetoplacental arterial strips [36] 
 cotyl. perf. increased foetoplacental vascular resistance [37] 
 cotyl. perf. < 10-14 M; foetoplacental vasodilation  
  higher doses; foetoplacental vasoconstriction [33] 
endothelins cotyl. perf. foetoplacental vasoconstriction [39;40] 
 myography constriction of foetoplacental arterial strips [41] 
hypoxia cotyl. perf. foetoplacental vasoconstriction [42;43] 
KV channel     VSMC patch clamp hyperpolarization of VSMC [34] 
                         EC patch clamp hyperpolarization of EC [44] 
KCa2+ channel  VSMC patch clamp hyperpolarization of VSMC [34] 
                         EC patch clamp hyperpolarization of EC [44] 
KATP channel  VSMC patch clamp hyperpolarization of VSMC [34] 
                         EC patch clamp none [44] 
nitric oxide cotyl. perf. foetoplacental vasodilation [3;4;33] 
 patch clamp hyperpolarization VSMC [34] 
prostacyclin myography dilation of foetoplacental arterial strips [36] 
 cotyl. perf. foetoplacental vasodilation [9;10] 
serotonin myography constriction chorionic and stem villous [45] 
thromboxane A2 cotyl. perf. foetoplacental vasoconstriction [9;13] 
cotyl. perf. = isolated perfused foetoplacental cotyledon 
VSMC = vascular smooth muscle cell 
EC = endothelial cell
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Baseline vascular tone is not only dependent on specific functional mediators. Non-
specific factors, like morphological characteristics and elasticity of resistance vessels 
may contribute to baseline vascular tone, as well. Morphological and human in-vivo 
studies point towards alterations in the structure and function of placental vessels in 
diabetes [46-48]. Additionally, the elasticity of resistance vessels (compliance) is 
reduced in diabetes [49]. However, no data exist on vascular compliance of 
foetoplacental vessels.  
 
 
Foetoplacental vascular function in preeclampsia 
Preeclampsia is a major complication of pregnancy. To date, the exact aetiology of the 
origin of preeclampsia remains uncertain. Like diabetes, preeclampsia is associated with 
endothelial dysfunction [50]. An impairment of endothelium-derived vasoconstrictor 
[51-54] as well as vasodilator [53;55;56] functions has been described in the 
foetoplacental vascular bed from patients with preeclampsia. Partly, oxidative stress 
may be an explanation for the origin of this endothelial dysfunction [22;57]. NO, the 
most important endothelium derived vasodilator in this vascular bed, is inactivated by 
reactive oxygen species (ROS), resulting in the formation of peroxynitrite. Peroxynitrite 
affects foetoplacental vascular function [22]. Administration of vitamin C and E to 
patients who ran the risk of developing preeclampsia seemed to be beneficial in the 
prevention of this disorder [58]. The effect of anti-oxidants on the foetoplacental 
circulation, however, is unknown.  
In different human vascular beds the antioxidants gluthation and its pharmacological 
precursor N-acetylcysteine (NAC), can improve endothelial function [59;60]. Such 
effect has been observed after short-term [59] as well as long-term administration [60]. 
In theory, administration of NAC into the foetoplacental vascular bed could improve 
endothelial function, especially the NO pathway, in women with preeclampsia. 
 
 
Placental transport function 
For the foetal well-being, the placenta has a role in respiration, nutrition, excretion, 
protection, storage, and hormone production. Exchange of gas, (micro)nutrients, 
hormones and excretion-products between maternal and foetal blood occurs over the 
so-called placental barrier. As mentioned, the human placenta is of the 
haemomonochorial type. This means that the placental barrier consists of a unilayer of 
syncytiotrophoblastic cells, a basal membrane and a unilayer of endothelial cells. From 
a pharmacological viewpoint, transport across the placental barrier can occur in four 
different ways; simple diffusion, facilitated diffusion, active transport, or pinocytosis. 
Glucose for example can pass the placental barrier freely through fascilitated diffusion. 
 21
GENERAL INTRODUCTION, OBJECTIVE AND OUTLINE 
Insulin, however, cannot pass the placental barrier at all. A disturbed placental uptake 
and transfer of nutrients, hormones and other products might result in an impaired 
placental as well as foetal growth and development.  
 
 
Folate transfer in foetal growth restriction 
An optimal transplacental transfer of (micro)nutrients is essential for development and 
growth of both the placenta and the foetus. Folate is an essential micronutrient in 
human beings. It plays an important role in a number of intracellular processes resulting 
in cell growth, such as carbon unit transfer, amino acid metabolism, and DNA 
synthesis. So, folate is involved in the development of the placental vascular bed, as 
well. 
A maternal folate deficiency is associated with several complications during pregnancy, 
including low birth weight [61-67]. Additionally, in vitro, folate deficiency induces an 
increase in apoptosis of the syncytiotrophoblast [68], probably due to a disturbed DNA 
synthesis and repair. Increased placental apoptosis during pregnancy is known to be 
associated with foetal growth restriction [69]. 
Additionally, folate is able to restore an impaired endothelial function. Folate does so, 
by increasing the activity of NO-synthase [70], and by reducing the catabolism of NO 
[71]. A such, apart from its effect on cellular growth and development, folate 
deficiency could result in an impaired vascular endothelial function. In theory, this 
endothelial dysfunction could be a second explanation for the increase in perinatal 
complications as observed in folate deficiency. 
The predominant form of folate in the human body is 5-methyltetrahydrofolic acid 
(5MTF). Cellular uptake of 5MTF is mediated by folate receptors in the microvillous 
plasma membrane. Three isotypes of the folate receptor (FR) have been described, of 
which only FRα is expressed in placental tissue [72]. FRα is a 
glycosylphosphatidylinositol-anchored protein located at the microvillous membrane. 
This receptor has direct contact with the maternal blood and binds folates with high 
affinity [73] with a dissociation constant for folic acid (pteroylglutamic acid) in the low 
nanomolar range [74-76]. After receptor-mediated uptake, folate efflux into the foetal 
blood is facilitated by the pH-dependent reduced folate carrier (RFC) at the basolateral 
side of the syncytiotrophoblast [72;77] (figure 5). 
 
To our knowledge only one study on the kinetics of human placental folate uptake has 
been published [78]. Placental uptake of 5MTF appeared not to be saturable at folate 
concentrations up to 1000 nM. During pregnancy, reduced availability of folate for the 
placenta or foetus can impair normal cellular growth and replication. This may arise 
from low folate intake or deficient placental uptake and subsequent transfer to the 
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foetal blood. No study has been performed yet on folate transport in placentae of 
pregnancies complicated by foetal growth restriction.  
 
 
microvillous membrane basolateral membrane
syncytiotrophoblast
RFC
FRα
5MTF
1
2
3
4
5
6
 
Figure 5 
Schematic presentation of human placental transfer of 5 MTF across the 
syncytiotrophoblast; 5MTF binds to  Folate Receptor-α (FRα) on the microvillous 
membrane (1), the FRα-5MTF complex is internalised into the syncytiotrophoblast via 
endocytosis (2, 3), 5MTF is released from FRα, probably due to a decrease of pH in the 
vesicles (4), 5MTF is transferred across the basolateral membrane by the Reduced 
Folate Carrier (RFC) (5,6) 
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OBJECTIVE AND OUTLINE OF THE THESIS 
 
The placenta has a key role in human reproduction. Moreover, it is a very exceptional 
organ; it combines functions which are performed by separate organs after birth. It 
transfers  (micro)nutrients, oxygen/carbondioxide, hormones and waste products 
between mother and the developing foetus without actually mixing maternal and foetal 
blood. The low-resistance foetoplacental vascular bed plays a key role in placental 
physiology. An undisturbed function of this vascular bed is important for an optimal 
development and growth of the foetus.  
Although some data are available on placental vascular function in healthy 
circumstances, the involvement of disturbed placental physiology in several 
complications of pregnancy remains under-exposed. The placental vascular bed lacks 
autonomic innervation [2], therefore local mediators, like endothelium derived 
vasoactive factors, are important for the regulation of foetoplacental vascular tone. 
Diabetes mellitus type 1 and preeclampsia are associated with vascular endothelial 
dysfunction [16;50]. Moreover, both diseases are associated with an increased 
perinatal morbidity and mortality. In theory, in both diseases endothelial dysfunction in 
the foetoplacental vascular bed could contribute to the occurrence of perinatal 
complications.  
The main objective of this thesis was to investigate the effect of diabetes mellitus type 
1 on foetoplacental vascular function (part I). Since maintenance of low-resistance is 
essential for an optimal placental function, it were mainly vasodilator mechanisms 
which were investigated. The effect of administration of the anti-oxidants vitamin C 
and NAC on the NO pathway in the foetoplacental circulation from preeclampsia (NAC) 
and healthy controls (vitamin C and NAC) was studied, as well (part II). Finally, 
placental transfer and binding of folate were investigated in placentae from pregnancies 
with foetal growth retardation as compared to controls (part III). 
 
 
Part I 
In chapter 2 the contribution of NO to the regulation of the baseline vascular tone in the 
foetoplacental circulation in DM was quantified. Additionally, the effect of insulin on 
the NO pathway in the foetoplacental vascular bed was investigated. These 
investigations were performed by means of ex vivo dual perfusion of the isolated 
human placental cotyledon. 
Chapter 3 describes a study on the contribution of different potassium channels to 
baseline vascular tone in the foetoplacental vascular bed in DM versus matched 
controls. Also, in this chapter the results of the study of the non-specific morphometry 
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and vascular compliance are presented. In part, this study was performed by use of ex 
vivo cotyledon perfusion as described in chapter 2. Additionally, the morphometric 
analysis was performed using the VIDASplus analysis system, and elasticity of 
foetoplacental resistance vessels was assessed by use of a pressure myograph. 
The contribution of cyclooxygenase products to baseline vascular tone in the 
foetoplacental vascular bed in DM as compared to controls was studied by ex vivo 
cotyledon perfusion in chapter 4.  
 
 
Part II 
In chapter 5 the contribution of the NO pathway to baseline vascular tone in this 
vascular bed in preeclampsia as compared to controls is described. Additionally, the 
effect of acute administration of vitamin C in the foetoplacental circulation in placentae 
from uncomplicated pregnancies was assessed.  
Chapter 6 describes the results of a study in which we investigated the effect of acute 
administration of NAC on the NO pathway in the foetoplacental vascular bed in 
placentae from women with mild preeclampsia as compared to placentae from healthy 
controls. In both these chapters, the studies were performed by ex vivo cotyledon 
perfusion. 
 
 
Part III 
In chapter 7 a comparison was made of the transplacental folate transfer, binding of 
folate to the FRα, and expression of FRα and RFC between placentae from controls, and 
those from pregnancies complicated with foetal growth restriction. Folate transfer was 
investigated by ex vivo cotyledon perfusion. Binding of folate to the FRα was studied 
with a radioligand binding assay on isolated microvillous membranes from 
syncytiotrophoblasts. The expression of FRα and RFC was studied by Western Blot 
analysis on the same microvillous membrane fraction as well as a crude mince from 
each placenta.  
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SUMMARY 
 
 
Endothelium-derived nitric oxide (NO) plays a key role in the regulation of vascular tone 
in health and disease. The present study addresses the contribution of NO to the 
baseline vascular tone in the foetoplacental circulation of type 1 diabetic women. To 
this end, we performed ex-vivo dual perfusions of isolated cotyledons from 7 women 
with type 1 diabetes mellitus and 24 healthy women. The foetoplacental arterial 
pressure was considered to be a measure of foetal vascular resistance. The contribution 
of NO to the baseline vascular tone of the foetoplacental circulation was quantified by 
addition of the NO-synthase inhibitor NG-nitro-arginine-methylester (L-NAME). Apart 
from the diabetic state, we studied the influence of exogenous insulin on the response 
to L-NAME.  
Mean (± SEM) baseline foetoplacental arterial pressure  was higher in diabetes (25.7 ± 
3.4 mm Hg versus 18.0 ± 1.7 mm Hg, P<0.05). Maximum perfusion pressure after L-
NAME was 87.9 ± 7.1 mm Hg in diabetes versus 58.9 ± 4.5 mm Hg in controls 
(P<0.01). The net L-NAME-induced increase in foetoplacental arterial pressure was 
higher in diabetes (62.2 ± 9.1 mm Hg versus 40.9 ± 3.5 mm Hg, P<0.05). Although 
insulin induced a shift to the left of the L-NAME-curve, the net L-NAME-induced 
increase in foetoplacental arterial pressure was not affected. 
We conclude that diabetes is associated with an increased baseline vascular tone of the 
foetoplacental vascular bed. This cannot be explained by attenuated NO-mediated 
effects. In contrast, the activity of the NO pathway seems to be increased in diabetes. 
The latter observation seems not to be caused by high insulin levels.  
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INTRODUCTION 
 
 
In women with diabetes mellitus type 1 (DM), pregnancy is associated with an 
increased risk for perinatal complications.  In part, this concerns complications like 
intrauterine growth retardation and foetal death [1], which may be explained by 
changes in the foetoplacental circulation. Indeed, DM is known to affect vascular 
function [2], and morphological as well as human in-vivo studies point towards 
alterations in the structure and function of placental vessels [3-5]. 
In the past decade, endothelium-derived nitric oxide (NO) has been identified as an 
important endogenous regulator of vascular tone. Also in the placental circulation, the 
endothelial release of NO significantly dilates the foetoplacental vascular bed [6;7]. In 
DM, hyperglycaemia has been reported to impair endothelium-dependent vasodilation 
[8], in particular by reducing the bioavailability of NO. The foetoplacental circulation of 
diabetic patients is not only exposed to high glucose concentrations, but also to high 
insulin, as hyperglycaemia will elicit insulin release from the foetal pancreas. 
Interestingly, high insulin levels have been reported to increase the endothelial release 
of NO [9]. Finally, structural diabetes-induced changes of the vascular wall may 
contribute to alterations of vessel function. All these effects have been observed in 
different vascular beds including the foetoplacental circulation [10]. However, up to 
now no data on the baseline release of NO from placental vessels are available. 
Realising that hyperglycaemia and hyperinsulinemia occur simultaneously in the 
foetoplacental circulation, the activity of the NO pathway is thought to be changed in 
diabetic women. Because the net effect of these different factors is not known, we 
aimed to quantify the contribution of NO to the regulation of the baseline vascular tone 
in the foetoplacental circulation of women with type 1 diabetes.  
 
 
 
METHODS 
 
 
Study population  
All pregnant women with type 1 diabetes mellitus were eligible to participate in this 
study. Controls were healthy pregnant women. Exclusion criteria for both diabetic 
women and healthy controls were multiple pregnancy, premature birth (<37 weeks 
gestation), retained placenta, pregnancy-induced hypertension (diastolic pressure > 90 
mmHg on two following occasions), preeclampsia and HELLP syndrome (hemolysis, 
elevated liver enzymes and low platelets). Women with diabetes mellitus type 2 or 
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gestational diabetes mellitus were excluded from this study as well. All women gave 
written informed consent. The local medical ethics committee approved this study. 
Maternal and umbilical venous blood samples for insulin and C-peptide assay were 
taken within 15 minutes after delivery.   
 
 
Placenta perfusion  
Placentae were obtained immediately following delivery. Within 15 minutes, a suitable 
cotyledon was selected for ex-vivo dual perfusion [11]. The third or fourth order artery 
and vein were cannulated just before passage through the chorionic plate. Foetal inflow 
was gradually increased to 6 ml/min, at which the baseline foetoplacental arterial 
pressure equilibrates to 15 to 40 mmHg. The cotyledon was placed in a chamber with 
the maternal side facing upward. Maternal inflow was kept constant at 12 ml/min. The 
maternal outflow was collected and returned into the maternal reservoir. The perfusion 
fluid (150 ml for both sides) was 37.0 – 37.5°C, and was oxygenated with 95% O2/ 
5% CO2 (pH 7,4).  
Because the foetal arterial inflow was kept constant, the foetoplacental arterial pressure 
was considered to be a reflection of the foetal arterial resistance. After 30 minutes of 
equilibration, the NO pathway in the foetal circulation was investigated by adding 
increasing concentrations of the NO-synthase blocker L-NAME. To study the effect of 
insulin in this model, half of the control placentae (n=12) were pre-treated with 
exogenous insulin (150 mE/ml)  at the foetal side, 15 minutes prior to L-NAME.  
 
 
Materials 
Perfusion fluid was a Krebs Henseleit buffer containing 121 mM NaCl, 4 mM KCl, 0.95 
mM KH2PO4, 1.2 mM MgSO4-7H2O, 22 mM NaHCO3, 11.1 mM glucose-H2O, 2 mM 
CaCl2. Heparin was used in a concentration that does not affect vascular tone (2500 
IE/L) [12]. L-NAME was obtained from Sigma (St. Louis, USA), human insulin (Actrapid) 
was obtained from Novo Nordisk Pharma B.V. (Alphen aan de Rijn, the Netherlands).  
Statistical analysis 
Comparison of the clinical characteristics was performed by a Mann-Whitney U test. 
Data on perfusion pressures were analysed using Prism 3.0 (Graphpad Software) by 
fitting individual concentration-response curves for each experiment.  For differences 
between groups, these data were tested by the Kruskall-Wallis test (SPSS).  For 
correlations, Spearman correlation coefficients were calculated.  
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Figure 1 
The mean (± SEM) change from baseline of the foetoplacental arterial pressure in 
response to increasing concentrations of the NO-synthase inhibitor L-NAME in diabetic 
women (DM, n=7, dashed line) versus healthy controls (n=12, solid line).   
 
 
 
RESULTS 
 
 
Clinical characteristics 
Seven placentae originated from women with DM and 24 placentae from healthy 
controls. Table 1 presents all relevant clinical characteristics of the participants. Besides 
a slightly lower maternal diastolic blood pressure and a shorter gestational age in DM, 
clinical characteristics between the groups were comparable.  
As expected maternal venous C-peptide concentration was decreased in DM (median 
and range: 0.20 nmol/l; 0 - 0.48) compared to the control group (0.88 nmol/l; 0.16 - 
2.31, p < 0.05), whereas umbilical insulin concentration (132 mE/ml; 28 - 242 versus 
19mE/ml; 6 - 54, p < 0.001) and umbilical C-peptide concentration (2.38 nmol/ml; 
0.47 – 4.16 versus 1.01 nmol/ml; 0.21 – 6.00, p< 0.05) were increased in DM. There 
was no difference in maternal venous insulin concentration between DM and controls. 
The pO2  in the foetal perfusion fluid observed during these experiments was 471 (392 - 
548) mm Hg. 
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Figure 2  
The mean (± SEM) change from baseline of the foetoplacental arterial pressure in 
response to increasing concentrations of the NO-synthase inhibitor L-NAME in 
healthy controls without insulin (n=12, solid line) versus healthy controls with 
insulin (n=12, dashed line). 
 
 
Type 1 diabetes mellitus versus healthy controls 
Baseline foetoplacental arterial pressure was increased in DM (mean ± SEM: 25.7 ± 3.4 
mm Hg versus 18.0 ± 1.7 mm Hg, P<0.05). Maximum foetoplacental arterial pressure 
at the highest dose of L-NAME was 87.9 ± 7.1 mm Hg in DM versus 58.9 ± 4.5 mm 
Hg in the control group (P<0.01). The L-NAME induced increase from baseline in 
foetoplacental arterial pressure was significantly higher in DM (62.2 ± 9.1 mm Hg 
versus 40.9 ± 3.5 mm Hg, p < 0.05) (figure 1). The logEC50 was similar in both groups  
(–4.3 ± 0.1 versus –4.5 ± 0.1). There was no correlation between baseline 
foetoplacental arterial pressure  and the maximum response to L-NAME.  
 
 
 
Insulin effects on the NO pathway in the foetoplacental circulation of healthy controls 
Addition of insulin prior to L-NAME did neither affect baseline foetoplacental arterial 
pressure (17.8 ± 1.7 with versus 18.0 ± 1.7 mm Hg without insulin), nor maximal 
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foetoplacental arterial pressure after L-NAME (57.9 ± 2.4 versus 58.9 ± 4.5 mm Hg). 
Also, the net L-NAME-induced increase in foetoplacental arterial pressure was not 
affected by insulin pre-treatment (40.2 ± 3.0 versus 40.9 ± 3.5 mm Hg) (fig 2). 
However, the logEC50 was lower when insulin was added (-4.9 ± 0.1 versus -4.5 ± 0.1, 
p < 0.01).  
 
 
 
DISCUSSION 
 
 
Although impaired endothelial function has been observed in all kind of diabetes 
models, little is known about foetoplacental vascular function in DM. In established 
DM, reduced NO-mediated effects have been put forward as a cause of vascular 
dysfunction [13;14], whereas the early stages of DM may show increased NO 
production [15;16]. We now observed that L-NAME-induced vasoconstriction was more 
pronounced in DM versus controls. This observation suggests that the contribution of 
NO to the baseline vascular tone is increased in the diabetic placentae. Since the newly 
formed vascular bed in the placenta is only exposed to the diabetic environment during 
the limited period of pregnancy, this particular vascular bed may show functional 
characteristics similar to other vascular beds in the early stages of diabetes.  As such, 
the present observation of an upregulated NO pathway in our material may be in line 
with previous findings in other vascular beds.  
The observed increased response to L-NAME could be a non-specific response rather 
than a  specific upregulation of the NO pathway in the diabetic placentae. However, in 
an identical study with another vasoconstrictor (glibenclamide, an ATP-dependent 
potassium-channel blocker which does not act via the NO pathway), we did not 
observe an increase in the maximal response in DM as compared to controls [17]. Other 
investigators even observed attenuated responses to vasoconstrictors like angiotensin II 
and the prostanoid analogue U46619 [10]. Together, these data strongly argue against 
a non-specific explanation for the upregulated NO pathway including the occurrence of 
structural vascular changes in the foetal vascular bed of diabetic patients.
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Table 1
Clinical characteristics of the participants (median, min - max)   
 Diabetes Control Control 
Number 7 12 12 
Maternal age (years) 34.2 (26.1 - 36-7) 35.3 (27.0 - 42.8) 31.6 (21.1 - 41.0) 
Parity (number) 0 (0 - 1) 1 (0 - 3) 0 (0 - 1) 
Gestation (weeks) 37.9 (37.0 - 38.9)∗ 39.9 (37.7 - 41.6) 39.8 (37.0 - 42.3) 
Birth weight (grams) 3610 (2780 - 4300) 3330 (2500 - 4560) 3622 (2760 - 4500) 
Placental weight (grams) 600 (500 - 740) 645 (400 - 815) 585 (400 - 1000) 
Body Mass Index (kg/m2) 26.9 (23.8 - 39.7) 25.2 (15.4 - 30.8) 23.5 (19.0 - 28.1) 
Diastolic BP (mm Hg) 75.0 (65.0 - 78.0) 82.0 (70.0 - 90.0) 80.0 (68.0 - 91.0) 
Smokers (number) 0 1 1 
Medication Insulin(n=7) 0 0 
White Class 3 C, 2 D, 1 F, 1 R - - 
HbA1c 1st trimester (%)1 6.1 (5.8 - 7.2) - - 
HbA1c 3rd trimester (%)1 6.0 (5.7 - 7.3) - - 
Insulin    (mE/ml)     M 28.6 (5.0 – 59.0) 28.2 (0.2 – 161.0) - 
                             U      131.4 (28.0 – 242.0)∗ 17.4 (5.0 – 54.0) - 
C-peptide (nmol/l)    M 0.20 (0.00 – 0.48)∗ 0.88 (0.16 – 2.31) - 
                             U 2.38 (0.47 – 4.16)∗ 1.01 (0.21 – 6.00) - 
∗ P<0.05 versus healthy controls, M = maternal, U = umbilical 
1 normal value for HbA1c in our laboratory is 4.2 – 6.3 % 
 
 
 
Our data show that the baseline vascular resistance of the foetoplacental vascular bed 
is slightly increased in DM.  Obviously, this observation cannot be explained by reduced 
NO-mediated effects in diabetes, because the data on L-NAME point towards the 
opposite. Vasodilator substances like prostacyclin and Endothelium Derived 
Hyperpolarizing Factor (EDHF) have been reported to be decreased in DM [18;19], 
whereas the production of vasoconstrictors like endothelin [20] were increased in other 
vascular beds in DM. Although those mechanisms would be compatible with our 
observations, no data on these specific mediators are available as far as the 
foetoplacental vascular bed is concerned. On the vasoconstrictor 
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 prostanoid thromboxane, specific data in the foetoplacental vascular bed show a 
reduced response in diabetes [21]. However, this appeared not to result in an altered 
baseline vascular resistance of diabetic placentae as observed in our study. 
 
Previous studies suggest that insulin triggers the release of endothelium-derived NO [9]. 
Since the foetoplacental circulation is exposed to high insulin in diabetes, this 
phenomenon may be the explanation for the observed increase in L-NAME-induced 
vasoconstriction. In our study, addition of insulin showed a shift to the left of the 
concentration-response curve of L-NAME, but the maximum increase in foetoplacental 
arterial pressure appeared not to be affected by insulin. As such, our data on insulin 
argue against a role for insulin in the increased vasoconstrictor response to L-NAME in 
diabetes, although the long-standing exposure to insulin in patients may have different 
effects than the short-term in-vitro exposure of the present study.  
 
In conclusion, our study in the foetoplacental circulation shows an increased baseline 
vascular resistance in type 1 diabetes as compared to controls. This increased baseline 
tone is not caused by reduced NO-mediated effects. In contrast, the NO pathway 
seems to be upregulated in diabetes as demonstrated by an elevated vasoconstrictor 
response to NO-synthase blockade. Increased concentrations of insulin seem not to be 
responsible for the increased vasoconstrictor response to L-NAME in diabetes.  
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DM AFFECTS FOETOPLACENTAL VASCULAR KATP CHANNEL 
SUMMARY 
 
 
The increased perinatal morbidity in diabetes may be partly related to vascular 
dysfunction. Since potassium channels play an important role in the regulation of 
vascular tone, this study explores the impact of diabetes on potassium channel function 
in the foetoplacental vascular bed.  
Vascular potassium channel function was investigated by ex-vivo dual perfusion of 
isolated placental cotyledons (n=47). Appropriate control experiments were carried out 
to exclude non-specific effects.   
Glibenclamide (KATP channel blocker) increased perfusion pressure to a maximum 
foetoplacental arterial pressure of 37 ± 6 mmHg in controls versus 15 ± 6 mmHg in 
diabetes (P<0.05). 4-Aminopyridine (KV channel blocker) equally increased 
foetoplacental arterial pressure in controls, and in diabetes (21 ± 4 mmHg versus 22 ± 
2 mmHg). Apamin and charybdotoxin (KCa channel blockers) caused a negligible rise in 
foetoplacental arterial pressure.  
In the foetoplacental circulation, KATP channels and KV channels significantly contribute 
to baseline vascular tone. In diabetes, vascular KATP channel function is impaired. 
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INTRODUCTION 
 
 
In diabetes, pregnancy is associated with an increased risk for perinatal complications 
[1], including foetal death. Theoretically, these complications can be explained by 
changes in the foetoplacental circulation, as vascular dysfunction may compromise 
optimal oxygenation of the vital organs of the foetus. Diabetes is known to affect 
vascular function, in both macro- and microcirculation. In particular, endothelial 
dysfunction is a rather common finding in diabetes [2-4]. Although the exposure to the 
diabetic environment is limited to the duration of pregnancy, previous experiments have 
shown that this period of time is sufficient to induce functional changes in the 
foetoplacental vasculature [5-6].  
The endothelium plays a pivotal role in the maintenance of baseline vascular tone. In 
diabetes, endothelial dysfunction, in particular with respect to the NO- and the 
cyclooxygenase pathways, have been observed in different vascular beds including 
foetoplacental arteries [5-6]. Apart from this, recent research points towards an 
impaired release of endothelium derived hyperpolarizing factor (EDHF) in diabetes [7]. 
Opening of the vascular smooth muscle KCa channel seems to be a final common 
pathway in the mechanism of action of EDHF. Independent from the EDHF-pathway, 
diabetes has been associated with dysfunction of the cardiovascular KATP channel, an 
ion channel that has an important role in the regulation of vascular tone during ischemia 
[8].  
We hypothesize that vascular potassium channel function in the foetoplacental 
circulation is compromised in diabetes.  To address this hypothesis, we assessed the 
vasoconstrictor response to potassium channel blockers in the foetoplacental vascular 
bed in diabetes versus controls. 
 
 
 
METHODS  
 
 
Study population 
Pregnant women with type 1 diabetes were eligible to participate. Controls were 
healthy pregnant women with uncomplicated pregnancies. Exclusion criteria for both 
groups were multiple pregnancy, premature birth (<37 weeks gestation), retained 
placenta, pregnancy-induced hypertension (diastolic pressure > 90 mmHg on two 
following occasions), and preeclampsia or HELLP syndrome (hemolysis, elevated liver 
enzymes and low platelets).  
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From all participants maternal and umbilical venous blood samples for insulin and C-
peptide assay were taken within 15 minutes after delivery. All women gave written 
informed consent. The local medical ethics committee approved this study. 
 
 
Classification of diabetes mellitus in pregnancy. 
In pregnancy diabetes mellitus is classified according to the White Classification. This 
classification consists of seven group; A, B, C, D, F, R, and H. Group A is the 
classification for gestational diabetes mellitus. Groups B, C, D, F, R, and H are 
classifications for pregestational diabetes mellitus. In groups B, C, and D the age of 
onset of diabetes mellitus in years (>20, 10 - 19, and <10 respectively), and duration 
of the disease in years (<10, 10 - 19, >20) determine the classification. Groups B and 
C are not associated with vascular complications; group D is associated with a benign 
nephropathy. In groups F, R, and H vascular complications determine the classification. 
Group F is associated with nephropathy, group R with retinopathy and group H with 
heart disease. 
 
  
Cotyledon perfusion  
Over a period of two years, all placentae from type 1 diabetic women were obtained 
immediately following delivery and transported to the laboratory within 10 minutes 
following delivery. Controls matched for mode of delivery, parity and maternal age, 
were acquired throughout this period. After arrival at the laboratory, a suitable 
cotyledon was selected from the placenta for ex-vivo dual perfusion as described 
extensively before [6]. With a constant foetal arterial inflow, the foetoplacental arterial 
pressure was considered to be a reflection of net downstream foetoplacental vascular 
resistance. The contribution of four different vascular potassium channels to baseline 
foetoplacental vascular tone was investigated by adding increasing concentrations of 
the selective blockers for these channels both in control and in diabetic placentae. 
These blockers were: glibenclamide for the ATP dependent K channel (KATP channel), 
apamine for the small conductance KCa2+ channel (SK channel); charybdotoxin for the 
intermediate conductance KCa2+ channel (IK channel), large conductance KCa2+ channel 
(BK channel), and some voltage dependent K channels (KV channel), and 4-
aminopyridine for the KV channel. These blockers were added in 6 to 9 cumulative log-
dose steps in concentration ranges from (log concentration [mol/L]):  –8.0 to –3.5 
(glibenclamide), -9.0 to –6.0 (apamin), -10.0 to –7.0 (charybdotoxin) and –7.5 to –3.5 
(4-aminopyridin). 
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Control experiments on vascular compliance of isolated resistance arteries 
In order to assess the elasticity of the resistance arteries (compliance) of control and 
diabetic placentae, foetoplacental resistance arteries were isolated from 4 healthy and 4 
diabetic patients. On isolation, all arteries were transferred to the 10-ml pressure 
myograph organ bath, where they were immersed in Ca-free medium as described 
previously by Smits et al. [9]. The artery was gradually pressurized to 50 mmHg in a 
pressure myograph (Danish MyoTech P100) over a period of 5 minutes, and the arterial 
diameter was studied by stepwise increasing the intraluminal pressure from 1 to 60 
mmHg for a period of 2 min at each pressure step. This was done twice in succession 
for each artery. The vessel diameter values for these two series were then averaged for 
each pressure. In this way two or three arteries were studied per placenta. These 
vessel diameter values were averaged to one representative value for each placenta. All 
preparations were gassed with 95% O2 / 5% CO2 in order to maintain pH at 7.4 
throughout the experiment. 
 
 
Control experiments on morphometry of the foetoplacental arterial circulation  
In order to quantify the vascular diameters and wall thickness we used the 
computerized image analysis system (e.g. Vidas PLUS system, Carl Zeiss GmbH, 
Germany) [10]. To perform this analysis, the vascular endothelial CD34 antigen was 
detected by the monoclonal mouse-anti-CD34 antibody (QBEnd) [10]. The Vidas PLUS 
system is organized in such way that it is able to discriminate the CD34-stained 
endothelium from the surrounding tissue. In 25 images of each placenta, the following 
vascularisation variables were calculated by the computer system: a) per image: 
vascular area as a percentage, vascular perimeter, and vascular number, and b) per 
vascular element: the area, the perimeter, and the diameter. 
 
 
Materials 
Apamine, 4-aminopyridine, and H2O2 were obtained from Sigma (St. Louis, USA), 
charybdotoxin was obtained from Alomone Laboratories (Jerusalem, Israel), 
Glibenclamide was obtained from Hoechst Marion Roussel, USA. Formalin was obtained 
from JTBaker (Deventer, The Netherlands), QBEnd was obtained from Biogenex (San 
Ramon, CA, USA), and horse antimouse and the ABC Elitekit were obtained from 
Vector Laboratories (Burlingame, CA, USA). Before each experiment the blockers were 
dissolved in Krebs-Henseleit buffer to a solution of 0.8 mmol/L, except for 4-
aminopyridine, which was dissolved in water.  
 
 51
DM AFFECTS FOETOPLACENTAL VASCULAR KATP CHANNEL 
 
Statistical analysis 
All data were tested for normality by Shapiro-Wilk test. Comparison of the clinical 
characteristics of the diabetic women versus the healthy controls was performed by a 
Mann-Whitney U test. Data on cotyledon perfusion pressures were analyzed using 
Prism 3.0 (Graphpad Software) by fitting individual concentration-response curves for 
each experiment. Maximal percentage changes were calculated by use of the quotient:  
[max. – baseline foetoplacental arterial pressure] /  baseline foetoplacental arterial pressure * 100.  
The resulting parameters did not show Gaussian distribution and were therefore tested 
by a Mann-Whitney U test. Differences were considered to be significant at P-values < 
0.05. Data concerning vascular compliance were compared by paired t-test. Vidas 
PLUS -data were tested by an unpaired t-test. All statistics were performed in SPSS 
(SPSS 10.0, SPSS Inc., Chigaco, IL, USA). 
 
 
RESULTS 
 
 
In total, 37 placentae were included in this study (19 controls, 18 diabetes). When 
possible, we investigated two cotyledons of each placenta simultaneously. In those 
cases, the 2 cotyledons were used for different series. As such, 26 control cotyledons 
versus 21 diabetes cotyledons were measured. For the separate potassium channel 
blocker series, all cotyledons originated from different placentae. 
Table 1 summarizes the clinical characteristics of the participants. Women with 
diabetes had a shorter gestational age at time of delivery. As expected, maternal 
venous C-peptide concentration was lower in diabetic patients versus controls. There 
was no difference in maternal insulin concentration between controls and diabetes. In 
umbilical venous plasma, the C-peptide concentration was lower in diabetes as 
compared with controls, but as expected higher than the maternal C-peptide 
concentrations. In umbilical venous plasma, insulin concentration was increased in 
diabetes as compared with controls.  
Overall, baseline foetoplacental arterial pressure was comparable in controls (n=19) 
versus diabetes (n=18) (22 ± 1 mmHg versus 24 ± 1 mmHg, mean ± SEM). 
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Table 1
Clinical characteristics of the participants (median and range)   
 Controls Diabetic women 
Number of women/placentae 19 18 
Number of cotyledons tested 26 21 
Maternal age (years) 33.1 (25.0 – 40.1) 30.5 (21.0 – 38.2) 
Parity (number) 1 (0 - 3) 1 (0 - 3) 
Gestation (weeks) 40 (38 – 42) 38 (37 - 39) ∗ 
Vaginal delivery (number) 14 13 
CS + locoregional anaesthetic (number) 4 5 
CS + general anaesthetic (number) 1 0 
Birth weight (grams) 3097 (2555 - 3970) 3525 (2435 - 4875) 
Placental weight (grams) 548 (370 - 700) 670 (400 - 950) ∗ 
Body Mass Index (kg/m2) 23.0 (17.7 – 26.8) 23.9 (17.2 – 45.9) 
Diastolic BP (mm Hg)1 79 (60 - 90) 87 (55 - 90) ∗ 
Smokers (number) 1 2 
White Class - 9 B, 6 C, 1 D, 1 F, 1 R 
HbA1c 1st trimester (%)2 - 6.5 (5.8 – 8.8) 
HbA1c 3rd trimester (%)2 - 6.5 (4.8 - 7.1) 
Insulin (mE/ml)      M 15.5 (0.2 – 161.0) 22.0 (5.0 – 59.0) 
                           U 10.0 (5.0 – 54.0) 52.0 (5.0 – 242.0) ∗ 
C-peptide (nmol/L) M 1.02 (0.16 – 2.35) 0.12 (0.00 – 0.48) ∗ 
                           U 0.50 (0.21 – 6.00) 0.26 (0.28 – 4.16) ∗ 
∗ P<0.05 versus healthy controls 
CS=caesarean section, M=maternal, U=umbilical 
1 diastolic BP was measured 0 to 6 days before delivery 
2 normal value for HbA1c in our laboratory is 4.2 – 6.3 %; in patients with diabetes is 
aimed at a value < 7.0 % 
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KATP channel blockade by glibenclamide 
Glibenclamide induced a concentration-dependent rise in foetoplacental arterial pressure 
to a maximum of 56 ± 6 mmHg in controls (n=7) versus 38 ± 4 mmHg in diabetes 
(n=6) (table 2). As a consequence, the absolute glibenclamide-induced increase in 
foetoplacental arterial pressure was significantly lower in diabetes (figure 1). Figure 2 
shows the percentage increments in foetoplacental arterial pressure for all K channel 
blockers in both groups. This figure also shows the impaired vasoconstrictor response 
to glibenclamide in diabetes. The LogEC50 for glibenclamide was similar in both groups.  
 
 
KV channel blockade by 4-aminopyridine 
Addition of 4-aminopyridine caused a significant rise in foetoplacental arterial pressure, 
which was equal in controls (n=7) and in diabetes (n=7) (P<0.001 in controls as well 
as in diabetes) (figure 1, figure 2). LogEC50 was similar in both groups (table 2). 
 
 
SK channel blockade by apamine and BK/IK channel blockade by charybdotoxin 
Both apamine and charybdotoxin only caused minor increments in foetoplacental arterial 
blood pressure (table 2, figure 2), both in controls (n=6) and in diabetes (n=4).  
 
 
Comparison of foetoplacental  vascular compliance between diabetes and control 
experiments 
In theory, the observed differences between controls and diabetes in the response to 
glibenclamide may relate to diabetes-induced structural changes in the vascular wall. 
Therefore, foetoplacental vascular compliance was studied. The diameter at an 
intraluminal pressure of 0 mmHg was 90 ± 20 µm in foetoplacental arteries from 
controls and 90 ± 3 µm (average ± SEM) in those from diabetes. The maximum 
diameter, measured at an intraluminal pressure of 60 mmHg, averaged 260 ± 35  µm 
(n=4) in controls and 270 ± 10 µm (n=4) in diabetes. The pressure-diameter 
relationship was similar between controls and diabetes. Figure 3 shows the absolute 
pressure-diameter relationship. The figure for the relative diameter as percentage of the 
diameter at maximal tested pressure of 60 mmHg is comparable (not shown). 
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Figure 1 
The increase in foetoplacental arterial pressure in response to glibenclamide (left panel) 
and 4-aminopyridine (right panel) in the placenta in controls (solid line) and in women 
with diabetes mellitus type 1 (dotted line) (mean ± SEM) 
 
 
 
Table 2. 
Mean ± SEM characteristics of the concentration-response curves for the four 
potassium channel blockers in the foetoplacental circulation 
 
Blocker 
 
Group 
Foetoplacental arterial pressure (mmHg) 
Baseline  At maximum   Max. increase    LogEC50
Glibenclamide Control   (n=7) 20 ± 1 56 ± 6 37 ± 6 -6.4 ± 0.2 
 Diabetes (n=6) 23 ± 3 38 ± 4 ∗ 15 ± 3 ∗  -6.4 ± 0.2 
4-Aminopyridine Control   (n=7) 22 ± 2 43 ± 4 21 ± 4 -5.2 ± 0.2 
 Diabetes (n=7) 26 ± 2 48 ± 2 22 ± 2 -5.0 ± 0.2 
Apamin Control   (n=6) 27 ± 2 37 ± 3 10 ± 2 -7.4 ± 0.2 
 Diabetes (n=4)  30 ± 3 38 ± 5 9 ± 3 -7.6 ± 0.3 
Charybdotoxin Control   (n=6) 23 ± 3 26 ± 3 4 ± 1 -8.5 ± 0.2 
 Diabetes (n=4) 23 ± 3 24 ± 3 1 ± 1 -10.2 ± 2.1 
∗ P < 0.05 as compared to control 
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Figure 2 
Maximal percentage increase in foetoplacental arterial pressure induced by the highest 
dose of the different potassium channel blockers in controls (open bars) and women 
with diabetes mellitus type 1 (dotted bars) (mean ± SEM). The maximum concentrations 
given were 0.3 mM for glibenclamide, 1 µM for apamin, 0.1 µM for charybdotoxin and 
0.3 mM for 4-aminopyridin. * = P < 0.05 as compared to controls 
 
 
 
Comparison of placental vascular morphometry between diabetes and control 
experiments 
The impaired vasoconstrictor response to glibenclamide in diabetes may also relate to 
anatomical differences in the vascular beds between controls and diabetes. Therefore 
we performed control experiments on morphometry in placentae from controls (n=5) 
and from women with diabetes (n=8).  
The diabetes placentae originated from patients with White Class B (n=2), Class C 
(n=4), and Class D (n=2). Consequently, none of the women with diabetes had a 
history of vascular disease. As shown in table 3, all values for the individual vessels 
were comparable between controls and diabetes.  
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Figure 3 
Inner diameter of foetoplacental resistance vessels from healthy controls (open bars) 
and women with diabetes mellitus type 1 ( mean ± SD) 
 
 
Table 3. 
Mean (± SEM) of some foetoplacental vascular parameters as calculated by the Vidas 
PLUS image analysis system in controls and DM  
 Healthy controls 
(n=8) 
Diabetes mellitus type 1 
 (n=7) 
P-value 
Per field    
       Vascular area (%)1 0.18 ± 0.01 0.18 ± 0.01 0.90 
       Perimeter (µm/mm2)2 0.064 ± 0.003 0.058 ± 0.005 0.32 
       Vascular count (N/mm2)3 960 ± 70 830 ± 130 0.39 
Per vascular element    
       Area (%) 207 ± 23 290 ± 74 0.28 
       Perimeter (µm) 69 ± 4 80 ± 11 0.33 
       Diameter (µm)  8.5 ± 0.4 9.6 ± 1.1 0.34 
1CD34 positively stained area/total chorionic area x 100  
2total perimeter of vascular elements/total chorionic area x 106  
3total number of vascular elements/mm2 chorionic area 
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DISCUSSION 
 
 
The key observation in this study is that the vascular KATP and KV channel function 
significantly contributes to the baseline vascular tone of the ex vivo human 
foetoplacental circulation. In diabetes, this effect appears to be impaired for the 
vascular KATP channel, but not for the vascular KV channel. Under resting conditions, the 
KCa channels hardly contribute to baseline foetoplacental vascular tone, neither in 
women with diabetes nor in healthy women.  
Opening of potassium channels in vascular smooth muscle cells induces vasodilation by 
hyperpolarizing the cell membrane. By this hyperpolarization, voltage sensitive calcium 
channels will close resulting in a fall in calcium influx, a fall in intracellular calcium 
concentration and subsequent vasorelaxation. In resting conditions, vascular potassium 
channels may be open or closed depending on the type of tissue [11,12]. In our set up, 
the foetoplacental vascular bed shows a clear vasoconstrictor response to 
pharmacological blockade of the KATP channel by glibenclamide. From these 
observations, we conclude that the KATP channel is opened in the ex vivo perfused 
foetoplacental vascular bed, and contributes to baseline vascular tone. A similar line of 
reasoning concerns the KV channel since we observed a relevant vasoconstrictor 
response to 4-aminopyridine.  
Our observation on an impaired function of the vascular KATP channel in diabetes 
mellitus is unique as far as the foetoplacental vascular bed is concerned. However, 
other investigators have observed similar data in other vascular beds in diabetes [6,12]. 
In theory, the attenuated response to glibenclamide in diabetes may be related to 
dysfunction of the vascular KATP channel itself, for example as a result of glycosylation.  
The ATP/ADP ratio is a major determinant of the open state probability of KATP 
channels. As such, hypoxia or metabolic stress is a well-known trigger for the opening 
of KATP channels. From a theoretical point of view, the vasoconstrictor response to 
glibenclamide may be explained by the fact that the cotyledon is relatively hypoxic in 
our perfusion model. An argument against this mechanism is that the perfusion fluid is 
oxygenated intensively resulting in a pO2 in the inflow perfusion fluid between 400 and 
550 mmHg. However, the tissue oxygenation may be different from normal values, 
since the perfusion fluid does not contain an oxygen carrier, and we were not able to 
measure the tissue oxygen content during perfusion.  Although previous experiments 
from our laboratory have shown a constant lactate production in the perfused 
cotyledon model, this does not imply a hypoxic state because the placenta has been 
shown to use the glycolysis pathway independent of the oxygen status [13]. Recently, 
the KV channel has been shown to play a role in the vasoconstrictor response to 
hypoxia in the human foetoplacental vascular bed [14]. These investigators observed a 
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hypoxia-induced increase in the perfusion pressure from 27 to 33 mmHg. In our test 
with the KV channel blocker 4-aminopyridine, the perfusion pressure rose from 22 to 43 
mmHg. Because the baseline perfusion pressure was low in our model, and the 
response to 4-aminopyridine was more pronounced than the reported response to 
hypoxia, we think that hypoxia could not have played an important role in our set up. 
During pregnancy the foetoplacental vascular bed may be exposed to ischemic insults, 
which can harm foetal development or even result in foetal death [15]. In theory, the 
effects of these ischemic periods on the vascular bed might be comparable to those in 
cardiac and brain tissue. In the latter organs, powerful endogenous mechanisms have 
been described against ischemic injury, like for example hypoxic vasodilation and 
ischemic preconditioning [16,17], both mechanisms that contribute to the optimal 
match between oxygen use and metabolic demand. The KATP channel has been shown 
to play a crucial role in these protective mechanisms [18]. Interestingly, diabetes 
mellitus has been associated with impaired ischemic preconditioning [19]. Our 
observation of an impaired vascular KATP channel function in the foetoplacental vascular 
bed in diabetes implies that the matching between oxygen supply and demand may be 
less optimal in these patients. Such a defect may contribute to a poor outcome of 
ischemic insults in the foetoplacental circulation in diabetes. Along this line of 
reasoning, the vascular KATP channel may be an interesting pharmacological target to 
improve perinatal morbidity and mortality in type 1 diabetes mellitus. 
Apart from effects on the vascular smooth muscle cell, potassium channel blockers 
may affect the endothelium. Studies on the contribution of potassium channels to 
endothelium-dependent vascular responses in human vessels show that this 
contribution is small or does not play a role at all [20,21]. As such, the primary site of 
action of potassium channel blockers is more likely to be the vascular smooth muscle 
cell than the endothelial cell. 
In theory, the impaired vasoconstrictor response to glibenclamide in diabetes might 
reflect a more non-specific defect in vasoconstrictor capacity. However, this seems not 
to be the case because the vasoconstrictor response to other stimuli (for example 4-
aminopyridine) is similar in diabetes versus controls. For the NO-synthase inhibitor L-
NAME, we previously observed an even more pronounced vasoconstrictor response in 
diabetes as compared to controls [6]. As such, our observation on an impaired 
vasoconstrictor response to glibenclamide in diabetes seems to be specific. This 
conclusion is supported by the fact that our compliance and morphometric studies did 
not reveal structural differences of the foetoplacental vessels between diabetes and 
controls. 
In 2001 Langer et al presented a study, which concluded that oral treatment with 
glibenclamide is a clinically effective alternative to insulin for the treatment of 
gestational diabetes [22]. Our study shows that vascular KATP channels  do have a 
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substantial role in the regulation of baseline foetoplacental vascular tone. Since 
glibenclamide blocks these KATP channels, this treatment could compromise placental 
vascular function. Nevertheless, the transfer of glibenclamide across the human 
placenta seems to be minimal [23]. Oral treatment with glibenclamide may therefore be 
expected to only minimally affect foetoplacental vascular function, and as such may be 
preferred over other sulfonylurea derivatives, which may cross the placenta.  
 
In conclusion, our human ex vivo study in the foetoplacental vascular bed shows that 
both the vascular KATP channel and the KV channel significantly contribute to the 
regulation of baseline vascular tone. In type 1 diabetes, the function of the 
foetoplacental vascular KATP channel appears to be impaired. 
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CYCLOOXYGENASE DYSFUNCTION IN THE FOETOPLACENTAL CIRCULATION IN DIABETES 
SUMMARY 
 
 
In diabetes, perinatal morbidity is significantly increased. This may partly be related to 
functional changes in the foetoplacental vascular bed. In diabetes models, a defect in 
the cyclooxygenase pathway is a common observation. Therefore, we hypothesise that 
the human foetoplacental circulation of diabetic patients is characterised by dysfunction 
of the cyclooxygenase pathway, as well.  
We performed ex-vivo perfusions of isolated placental cotyledons from healthy women 
(n=14) and from patients with type 1 diabetes (n=9). The contribution of 
cyclooxygenase products to foetoplacental vascular tone was quantified by measuring 
the response to the cyclooxygenase inhibitor indomethacin.   
Baseline foetoplacental arterial pressure was comparable between controls and diabetic 
women (mean ± SEM, 21.7 ± 1.2 mmHg versus 24.4 ± 2.0 mmHg). Maximum 
foetoplacental arterial pressure at highest dose of indomethacin was 32.8 ± 3.0 mmHg 
in controls versus 27.3 ± 2.3 mmHg in diabetic women. The indomethacin-induced 
increase in pressure was reduced in diabetes (2.9 ± 0.7 mmHg versus 11.2 ± 2.4 
mmHg in controls, P=0.01).  
Under baseline conditions, the net effect of all cyclooxygenase products in the 
foetoplacental vascular bed is vasodilation. In diabetes, this vasodilator effect seems 
significantly impaired. 
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INTRODUCTION 
 
 
In diabetes mellitus type 1, pregnancies are more frequently complicated by intrauterine 
growth retardation and foetal death [1]. Since diabetes is known to affect vascular 
function [2], these complications may in part be explained by functional changes in the 
foetoplacental circulation. Under physiological conditions, the baseline vascular tone of 
the foetoplacental circulation is low. The endothelial release of prostanoids is expected 
to contribute significantly to the low-pressure state of the foetoplacental circulation. In 
diabetes, dysfunction of the cyclo-oxygenase pathway has been shown in several 
vascular beds, even in patients without micro- or macrovascular complications [3]. 
Therefore, we hypothesize that the exposure of the foetoplacental vascular bed to the 
diabetic environment  throughout pregnancy may result in a dysfunction of the 
cyclooxygenase pathway in this specific vascular bed. To address our hypothesis, we 
quantified the vasoconstrictor response to the cyclo-oxygenase blocker indomethacin 
by ex-vivo dual perfusion of isolated cotyledons from human placentae, both in healthy 
women and in patients with type 1 diabetes mellitus. 
 
 
 
PATIENTS AND METHODS 
 
 
Study population 
The experimental protocol was approved by the Medical Ethical Review Committee, and 
all participants gave written informed consent. All pregnant women with type 1 
diabetes were eligible to participate in this study. Controls were healthy women with 
uncomplicated pregnancies. Exclusion criteria were multiple pregnancy, premature birth 
(<37 weeks gestation), retained placenta, pregnancy-induced hypertension (diastolic 
pressure > 90 mmHg on two following occasions), preeclampsia, and type 2 or 
gestational diabetes mellitus.  
In all cases, maternal and umbilical venous blood samples for insulin and C-peptide 
determination were taken within 15 minutes after delivery.   
 
Placenta perfusion  
Within 15 minutes after delivery of the placenta, a suitable cotyledon was selected for 
ex-vivo dual perfusion [4], as previously described by our laboratory [5]. The third or 
fourth order artery and vein were cannulated just before passage through the chorionic 
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plate. Foetal inflow was gradually increased to 6 ml/min, at which the baseline foetal 
arterial pressure equilibrates to 15 to 40 mmHg. The cotyledon was placed in a 
chamber with the maternal side facing upward. Maternal inflow was kept constant at 
12 ml/min. The maternal outflow was collected and returned into the maternal 
reservoir. The perfusion fluid (150 ml for both sides) was 37.0 – 37.5°C, and was 
oxygenated with 95% O2/ 5% CO2 (pH 7,4). Because the foetal arterial inflow was 
kept constant, the foetal arterial pressure was considered to be a reflection of the 
foetal arterial resistance. After equilibration, the response of the foetoplacental arterial 
pressure to increasing concentrations of the cyclooxygenase-inhibitor indomethacin was 
investigated.. Indomethacin was added as a bolus injection into the foetal circulation in 
seven cumulative  dosages (1 nM to 1 µM). After each dose, stabilization of the 
foetoplacental arterial pressure was awaited, which took maximally 30 min, before we 
added the next dose. 
Materials  
Krebs-Henseleit buffer was used for perfusion. Just before each experiment, 
indomethacin (Sigma, St. Louis, USA) was freshly prepared. 
  
Statistical analysis  
Clinical characteristics were compared by Mann-Whitney U test. Data on perfusion 
pressures were analysed using Prism 3.0 (Graphpad Software) by fitting individual 
concentration-response curves according to the sigmoid Emax model for each 
experiment.  The indomethacin induced rise was calculated for each curve from the 
maximum foetoplacental pressure at highest dose of indomethacin, and the baseline 
foetoplacental pressure. Differences between groups were tested by the Kruskall-Wallis 
test (SPSS, SAS Institute, Cary, NC, USA).   
 
 
 
RESULTS 
 
 
Clinical characteristics of the participants 
Table 1 presents the clinical characteristics of the 14 healthy controls and the 9 
patients with diabetes. Gestational age at delivery was shorter in diabetic patients 
because in this group labour is electively induced at 38 weeks in our hospital. Despite 
the exclusion of hypertension, mean diastolic blood pressure was higher in diabetic 
women as compared to controls. All women had a spontaneous onset of labour. In 4 
diabetic women , a caesarean section had to be performed for the reason of prolonged 
labour. 
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There was no difference in maternal venous insulin concentration between the groups. 
Maternal venous C-peptide concentration was lower in diabetes as compared with 
controls. Umbilical venous C-peptide and insulin concentrations were increased in 
diabetes (table 1).  
 
 
 
 
Table 1
Clinical characteristics of the participants (median and range)   
 Control Type 1 Diabetes 
Number 14 9 
Maternal age (years) 32.8 (22.8 – 37.2) 31.4 (27.5 – 38.0) 
Parity (number) 0 (0 - 2) 1 (0 - 2) 
Gestational age at delivery (weeks) 39.9 (38.6 - 41.3) 38.0 (37.0 - 38.6) ∗ 
Caesarian Section (number) 0 4 
Birth weight (grams) 3115 (2505 – 3775) 3415 (2670 - 4875) 
Placental weight (grams) 525 (370 - 680) 690 (435 - 950) ∗ 
Body Mass Index (kg/m2) 24.7 (18.6 – 27.6) 28.0 (20.6 – 35.9) 
Diastolic Blood Pressure (mmHg) 75.0 (60.0 - 90.0) 89.0 (55.0 - 90.0) ∗ 
Smokers (number) 1 1 
Medication Paroxetine (n=1) Insulin (n=9) 
Induced labour with PGE2 (number (%) 1 (7) 9 (100) * 
White Class - 4 B, 2 C, 1 D, 1 F, 1 R 
HbA1c 1st trimester (%)1 - 6.2 (5.0 – 8.3) 
HbA1c 3rd trimester (%)1,2 - 6.1 (4.8 - 7.1) 
Insulin (mE/ml)      M 20.0 (0.2 – 161.0) 28.0 (5.0 – 59.0) 
                           U 14.5 (6.0 – 49.0) 79.0 (28.0 – 216.0) ∗ 
C-peptide (nmol/l)  M 0.97 (0.12 – 2.31) 0.12 (0. 00 – 0.27) ∗ 
                           U 0.55 (0.21 – 6.00) 1.61 (0.76 – 4.16) ∗ 
∗ P<0.05 versus healthy controls  
1 normal value for HbA1c in our laboratory is 4.2 – 6.3 %, 
2determined between 32 and 37 weeks gestation; median 34 weeks 
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Ex vivo perfusion of the isolated cotyledon 
Baseline foetoplacental arterial pressure was comparable between controls and diabetic 
women (21.7 ± 1.2 mmHg versus 24.4 ± 2.0 mmHg, mean  ± SEM). Maximum 
foetoplacental arterial pressure at the highest dose of indomethacin was 32.8 ± 3.0 
mmHg in controls, versus 27.3 ± 2.3 mmHg in diabetic women. In diabetes, however, 
the indomethacin induced rise in foetoplacental arterial pressure was significantly 
reduced (2.9 ± 0.7 mm Hg versus 11.2 ± 2.4 mm Hg in controls, P = 0.01) (figure 1). 
LogEC50 was similar in both groups (–7.4 ± 0.2 mol/L in controls versus –7.8 ± 0.2 
mol/L in diabetes).  
 
 
∆ Fetoplacental arterial pressure (mmHg)
-9 -8 -7 -6
0
5
10
15
                       
Indomethacin (logM)
Figure 1 
Mean (± SEM) indomethacin-induced increase in foetoplacental arterial pressure in type 
1 diabetes (n=9, dashed line) versus controls (n=14, solid line) 
 
 
DISCUSSION 
 
 
This study shows that inhibition of cyclooxygenase by indomethacin induces 
vasoconstriction in the ex vivo perfused foetoplacental vascular bed from healthy 
women. This implies a more important role for vasodilator prostanoids like prostacyclin 
than for vasoconstrictor prostanoids like thromboxane A2 in this particular vascular bed. 
Moreover, the vasoconstrictor response to indomethacin is decreased in diabetes, 
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suggesting a defect in the cyclooxygenase pathway in these patients. Since the low-
pressure state of the foetoplacental circulation is largely dependent on the release of 
local vasodilator substances, our observation may be of relevance with respect to the 
increased perinatal mortality and morbidity in diabetes.  
A defect in the cyclooxygenase pathway is a rather common finding in diabetes 
models. However, we now report on a very specific vascular bed, which is exposed to 
the diabetic environment for the limited period of nine moths. Despite this short 
exposure, a clear difference was found between and diabetic and control patients. In 
previous studies, we already reported on alterations in vascular reactivity in the 
foetoplacental vascular bed in patients with diabetes [5]. Apparently, 38 weeks of 
pregnancy is long enough to induce clear changes in vascular function in the 
foetoplacental circulation. 
At baseline, perfusion pressure did not differ between groups. Based on the observed 
defect in the cyclooxygenase pathway, an increase in baseline vascular tone would be 
expected in diabetes. Apparently, other vasodilator mechanisms have compensated for 
this defect. The most probable candidate is the nitric oxide pathway, as we previously 
found an increased vasoconstrictor response to NO synthase-inhibition by L-NAME in 
diabetes [5].  
Cyclooxygenase is involved in the formation of both prostacyclin and thromboxane A2, 
by stimulating the initial formation of prostaglandin endoperoxides from arachidonic 
acid. In a second step, PGI2 and TXA2 are formed by PGI-synthase and TXA-synthase 
respectively. Cyclooxygenase is involved in the formation of other prostanoids as well, 
although these are less relevant to vascular function. Although the total effect of the 
cyclooxygenase products on foetoplacental vascular tone is clear from our study, we 
are not informed on the respective contribution of PGI2 and TXA2. In theory, our data 
can be explained by both, an increased release of TXA2 and a reduced release of PGI2. 
In the literature, there is support for the latter mechanism since dysfunction of PGI2-
synthase may be caused by peroxynitrite [6,7], a radical oxygen species that is found 
to be increased in the foetoplacental vascular bed of diabetic patients [8]. Although 
increased synthesis of vasoconstrictor prostanoids has been suggested to occur in 
diabetes models, no such data are available concerning to the foetoplacental 
circulation. One study has reported on a reduced vasoconstrictor response to TXA2 as a 
result of a decrease in receptor affinity in placentae from patients with diabetes [9], but 
no data on the release of TXA2 were available. Of course, within the concept of 
receptor desensitisation, a reduced response would be compatible with an increased 
release of TXA2.  
The enzyme cyclooxygenase is known to exist in two isoforms; the cyclooxygenase-1 
and cyclooxygenase-2. The cyclooxygenase-1 is expressed in most tissues and is 
responsible for the majority of the vascular effects of cyclooxygenase. Under baseline 
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conditions, the expression of cyclooxygenase-2 is low in almost all tissues. It is 
responsible for the response to tissue damage, and can be upregulated by 
(patho)physiological conditions, such as ischemia and infection. In our model we did  
not investigate the differences between selective inhibitors for both cyclooxygenase-1, 
and cyclooxygenase-2. Indomethacine is known as a combined cyclooxygenase-1/ 
cyclooxygenase-2 inhibitor. In theory, most of the vascular effects of indomethacin 
may be attributed to the effects of inhibition of cyclooxygenase-1. Studies on the role 
of cyclooxygenase-2 in vascular function are limited. We can not exclude that the use 
of selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors would have resulted in 
different observations in our study.   
Insulin interacts with the cyclooxygenase pathway [10]. The most important interaction 
is the stimulation of prostacycline release by insulin [10].  If this mechanism was 
operative in our model, an increased vasoconstrictor response to cyclooxygenase-
inhibition would have been expected. Actually, we observed the opposite. This 
discrepancy may be explained by the fact that the vasculature in our ex vivo model is 
not exposed to the in vivo concentrations of insulin during the experiment. As such, 
due to stimulation of prostacyclin production by high insulin levels, the in-vivo effects 
of cyclooxygenase inhibition on the foetoplacental vascular bed from women with 
diabetes may be different from our observations. 
Additionally, the use a buffer solution may be a limitation of our study because this 
excludes the interactions between prostanoids and blood cells. As such, the 
observations in this study are limited to the effects of prostanoids released from the 
vascular wall. The advantage of our approach is that we are sure that our observations 
refer to the vascular wall and not to indirect effects via blood cells. 
Prostaglandin E2 (PGE2) is applied (para)cervically to induce labour, and is known as a 
vasoconstrictor in the placental circulation [11]. As such, the use of PGE2 may have 
confounded our observations. However, a comparison of baseline foetoplacental arterial 
pressures from this and earlier studies, showed no effect of exogenous PGE2 in controls 
nor in diabetic women (results not shown). In the present study, no such comparison 
could be made, because in all diabetic women labour was induced with PGE2. The 
absence of an effect of PGE2 on baseline pressure suggests that the paracervically 
applied substance does not reach the foetoplacental circulation. Unfortunately, we 
cannot exclude an effect of PGE2 on the response to indomethacin. 
 
In conclusion, under baseline conditions, the net effect of all cyclo-oxygenase products 
is vasodilation in the foetoplacental vascular bed. In type 1 diabetes mellitus this 
vasodilator effect is significantly impaired.   
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EFFECT OF VITAMIN C ON DISTURBED NO-PATHWAY IN PREECLAMPSIA 
SUMMARY 
 
Preeclampsia is associated with endothelial dysfunction, which is often related to 
oxidative stress. Oxidative stress might result in reduced effects of the endothelium-
derived-relaxing-factor nitric oxide (NO). Antioxidants remove reactive oxygen species, 
resulting in an improvement of endothelial function. In this study, we investigated the 
contribution of the NO pathway to baseline vascular tone in the foetoplacental 
circulation from preeclampsia as compared to healthy controls. Additionally, we 
investigated if vitamin C, possessing antioxidant capacities, has a beneficial effect on 
the NO pathway in the human foetoplacental circulation in control pregnancies.  
We did so by use of the NO-synthase inhibitor L-NAME in an ex vivo cotyledon 
perfusion model. Cotyledons from 30 placentae were used in this study; 4 from women 
with preeclampsia, and 26 from healthy controls. Within the latter group 12 cotyledons 
were investigated after administration of 5 mmol/L vitamin C.  
At baseline, foetoplacental arterial pressure was comparable in all groups. The 
maximum L-NAME-induced rise in foetoplacental arterial pressure was attenuated in 
preeclampsia as compared to controls (39 ± 6.5 mmHg (mean ± SEM) versus 49 ± 2.1 
mmHg, P < 0.05).  Addition of vitamin C increased the maximum L-NAME-induced rise 
in foetoplacental arterial pressure to 77 ± 4.9 mmHg (P < 0.001). LogEC50 was 
comparable between the controls and preeclampsia (-4.6 ± 0.2 mol/L vs. –4.6 ± 0.2 
mol/L). Addition of vitamin C, however, reduced the logEC50 to –5.1 ± 0.2 mol/L). 
In conclusion, the NO-mediated vasodilator component seems to be decreased in the 
foetoplacental vascular bed in preeclampsia as compared to controls. Administration of 
vitamin C increases the contribution of the NO pathway to baseline vascular tone in this 
vascular bed in controls.  
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INTRODUCTION 
 
Preeclampsia is a major complication of pregnancy. Although the exact aetiology of the 
origin of preeclampsia remains uncertain, preeclampsia is associated with endothelial 
dysfunction [1]. Defective trophoblast invasion is one of the early pathophysiological 
features that occurs before the development of the maternal syndrome [2]. In the full-
grown foetoplacental vascular bed from women with preeclampsia an impairment in 
endothelium derived vasoconstrictor [3-6] as well as vasodilator [6-8] functions has 
been described. Lucy Chappell and colleagues [9] reason that endothelial dysfunction 
and reduced bioavailability of nitric oxide (NO) contribute to oxidative stress, in 
particular from the interaction between superoxide anion and NO-producing 
peroxynitrite radicals. Indeed, partly, oxidative stress might be an explanation for the 
origin of this endothelial dysfunction [10-11]. NO, the most important endothelium 
derived vasodilator in this vascular bed, is inactivated by reactive oxygen species 
(ROS), resulting in the formation of peroxynitrite, which affects foetoplacental vascular 
function [11]. In-vitro experiments have shown that vitamin C interferes with this 
reaction, thereby increasing the availability of NO [12]. Chappell and colleagues’ 
positive results on the ratio of plasminogen-activator inhibitor 1 and 2, and on clinical 
outcome, are comparable with a vitamin-C induced improvement of the endothelial NO 
pathway. As such, supplementation with the vitamin C and E to patients who run the 
risk of developing preeclampsia seemed to be beneficial to the prevention of this 
disorder [9]. The effect of anti-oxidants in the foetoplacental circulation, however, is 
unknown. We investigated the NO pathway in the human foetoplacental circulation 
from women with preeclampsia and healthy controls, using the perfused cotyledon 
technique to assess endothelial function. Additionally, we investigated the effect of 
acute administration of vitamin C on the contribution of the NO pathway to baseline 
foetoplacental tone in healthy controls. 
 
 
 
METHODS 
 
 
The Medical Ethical Review approved the experimental protocol. All patients gave their 
informed consent. 
 
Study population 
Pregnant women with preeclampsia were eligible to participate in this study. 
Preeclampsia was defined as a diastolic blood pressure ≥ 100 mmHg measured at least 
 79
EFFECT OF VITAMIN C ON DISTURBED NO-PATHWAY IN PREECLAMPSIA 
two times with an interval of 4 hours, in combination with proteinuria defined as a > 
300 mg/24 h. Controls were healthy women after uncomplicated, normotensive 
pregnancy. Exclusion criteria were diabetes mellitus, multiple pregnancy, premature 
birth (<37 weeks gestation), foetal growth retardation, retained placenta, and HELLP 
syndrome (hemolysis, elevated liver enzymes and low platelets).  
 
 
Placenta perfusion  
Placentae were obtained immediately following delivery. Within 15 minutes, a suitable 
cotyledon was selected for ex-vivo dual perfusion [13]. The third or fourth order artery 
and vein were cannulated just before passage through the chorionic plate. Foetal inflow 
was gradually increased to 6 ml/min, at which the baseline foetoplacental arterial 
pressure equilibrates between 15 to 40 mmHg. The cotyledon was placed in a chamber 
with the maternal side facing upward. Maternal inflow was kept constant at 12 ml/min. 
The maternal outflow was collected and returned into the maternal reservoir. A 
recirculating system was used for both foetal and maternal side. The perfusion fluid 
(Krebs-Henseleit buffer without albumin, pH 7.4: 150 ml for both sides) was 37°C, and 
was oxygenated with 95% O2 and 5% CO2.  
Because the foetal arterial inflow was kept constant, the foetoplacental arterial pressure 
was considered to be a reflection of the foetoplacental arterial resistance. After 30 
minutes of equilibration, when the remnant blood had been washed out and the 
foetoplacental arterial pressure was stabilised, the experiment was started. The NO-
mediated component of baseline vascular tone in the foetal circulation was investigated 
by addition of the specific NO-synthase blocker N(G)-nitro-arginine-methyl-ester (L-
NAME) over a concentration range from 1 to 500 µM in a cumulative way. L-NAME 
was added to the foetal circulation in six dosages. After each addition stabilization of 
the foetoplacental arterial pressure was awaited, which took maximally 30 min, before 
we added the next dose. In 12 of the cotyledons from placentae from uncomplicated 
pregnancies, fifteen minutes prior to the first dose of L-NAME, vitamin C was dissolved 
in the Krebs Henseleit buffer (KH buffer) in the foetal perfusion fluid, to a final 
circulating concentration of 5 mmol/L. 
 
 
Materials 
A KH buffer containing 121 mM NaCl, 4 mM KCl, 0.95 mM KH2PO4, 1.2 mM MgSO4-
7H2O, 22 mM NaHCO3, 11.1 mM glucose-H2O, and 2 mM CaCl2 was used as perfusion 
fluid. Heparin was used in a concentration that does not affect vascular tone (2500 
IE/L). L-NAME and vitamin C were obtained from Sigma (St. Louis, USA).  
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Statistical analysis  
Comparison of the clinical characteristics was performed by a Mann Whitney U test. 
Data on perfusion pressures were analysed using Prism 3.0 (Graphpad Software) by 
fitting individual concentration-response curves to L-NAME for each experiment. For 
each experiment, the relevant curve characteristics were calculated. These were 
baseline foetoplacental arterial pressure, maximum L-NAME-induced foetoplacental 
arterial pressure, logEC50 [log of concentration at which 50% of maximum pressure 
occurred], and Hill slope. For differences between groups these curve characteristics 
were compared by one-way ANOVA, with post-hoc Tukey’s multiple comparison. 
 
 
 
RESULTS 
 
 
We studied 30 cotyledons, four from patients with preeclampsia, and 26 from 
normotensive women with pregnancies without complications. Within the latter group, 
12 cotyledons were investigated after co-administration of 5 mmol/L vitamin C. 
 
 
Table 1 
Clinical characteristics  
 Control Preeclampsia 
   
Number 26 4 
Maternal age (years) 32.1 (26.8 – 38.8) 29.5 (20.8 – 37.0) 
Parity (n) 2 (0 – 3) 0 (0 – 1) 
Gestational age (weeks) 40.0 (38.1 – 42.0) 37.1  (36.3 – 38.3) ∗ 
Birth weight (grams) 3795 (2550 – 4560) 2619 (1775 – 3700) ∗ 
Placental weight (grams) 600 (400 – 800) 400 (345 – 500) ∗ 
Body Mass Index (kg/m2) 24.2 (18.8 – 30.4) 28.6 (21.0 – 32.7) 
Diastolic blood pressure (mmHg) 77.2 (70.0 – 90.0) 98.0 (90.0 – 110.0) ∗ 
Caesarean section (n)  12 (46 %) 2 (50%) 
Smokers (n) 5 (19%) 1 (25%) 
Data are given as medians (min-max) or numbers 
∗ = P < 0.05 
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Clinical characteristics 
The clinical characteristics from the women that participated in this study are presented 
in table 1. All women with preeclampsia had a proteinuria > 300 mg/24h, whereas all 
other women had no proteinurea. As expected diastolic blood pressure was increased in 
preeclampsia, and birth and placental weight were decreased as compared to controls.  
 
 
Effects of L-NAME in isolated cotyledons 
There were no differences in baseline perfusion pressures between groups. In 
cotyledons from preeclamptic women, L-NAME increased the perfusion pressure 
concentration dependently from mean 14 ± 4 mmHg (mean ± SEM) to 39 ± 6.5 
mmHg (figure 1). This vasoconstrictor response was significantly higher in 14 
cotyledons from healthy pregnant women (16 ± 3 mmHg to 49 ± 2.1 mmHg, P < 
0.05 vs. controls). LogEC50 was the same in controls (-4.6 ± 0.2 mol/L) as in women 
with preeclampsia (-4.6 ± 0.2 mol/L). Hill slopes were similar in all three groups, and 
were not significantly different from 1.0.  
 
Fetal arterial pressure (mmHg)
-9-8
0
25
50
75
100
-6 -5 -4 -3 -2
  L-NAME (logM)
 
 
Figure 1 
L-NAME-induced rise in foetoplacental arterial pressure in healthy controls without (○) 
and with ( ●) addition of vitamin C, and preeclampsia without (□). 
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Effects of vitamin C 
In 12 cotyledons exposed to vitamin C the vasoconstrictor response to L-NAME was 
greatest (14 ± 9 mmHg to 77 ± 4.9 mmHg, P < 0.001 vs. controls without vitamin 
C). LogEC50 was significantly lower in the vitamin C group (-5.1 ± 0.2 mol/L), P < 
0.001 vs. other groups).  
 
 
 
DISCUSSION 
 
 
These results suggest that the NO-mediated contribution to baseline foetoplacental 
vascular tone is increased in controls as compared to that in women with preeclampsia. 
Additionally, the contribution of the NO pathway to baseline tone was increased in the 
presence of vitamin C. 
NO has been identified as an important endogenous regulator of baseline vascular tone. 
Also in the placental circulation, the endothelial release of NO significantly dilates the 
foetoplacental vascular bed [14;15]. Our study suggests that the contribution of NO to 
baseline vascular tone is decreased in preeclampsia. In contrast with these results, an 
increased production of NO [16;17], and en increased expression of eNOS [18] have 
been reported in this vascular bed in preeclampsia.  However, recently others did not 
observe a dysfunction of eNOS in preeclampsia [19]. As such, despite an increased 
production of NO in preeclampsia, its function seems to be disturbed. Reason for this 
may be that NO is rapidly inactivated by the superoxide-anion, resulting in the 
formation of peroxynitrite. Peroxynitrite is increased in the foetoplacental vascular bed 
in preeclampsia, and affects [20] foetoplacental vascular function [11]. 
Vitamin C is a potent water-soluble antioxidant [21]. The effect of vitamin C on 
vascular function has been beneficial in different human vascular beds under various 
pathological conditions [22;23], however, no data exist on the foetoplacental vascular 
bed. It is unlikely that this beneficial effect of vitamin C is a result of scavenging of the 
superoxide radical, because the interaction between the superoxide radical and NO has 
place rapidly with a high rate constant of about 1.9 1010 M/s [24]. As such, the 
mechanism of action of vitamin C remains elusive. 
 
In conclusion, the contribution of NO to baseline vascular tone is impaired in the foetal-
placental circulation from patients with preeclampsia. Vitamin C is able to increase the 
NO-mediated vasodilator component in this vascular bed from healthy controls.  
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NAC AMELIORATES NO PATHWAY IN PREECLAMPSIA 
SUMMARY 
 
 
Preeclampsia is associated with an imbalance between oxidants and anti-oxidants 
resulting in reduced effects of the endothelium-derived-relaxing-factor nitric oxide (NO). 
Antioxidants, like N-acetylcysteine (NAC) remove reactive oxygen species, resulting in 
an improvement of endothelial function. We aimed to investigate the effect of NAC on 
the NO pathway in the human foetoplacental circulation in preeclampsia and control 
pregnancies.  
The NO pathway was investigated by use of the NO-synthase inhibitor L-NAME in an 
ex vivo cotyledon perfusion model.  
At baseline, foetoplacental arterial pressure was comparable in preeclampsia (n=8) and 
controls (n=8), and increased dose-dependently after L-NAME. The maximal L-NAME-
induced rise in foetoplacental arterial pressure was attenuated in preeclamptic 
pregnancies versus controls (20.8 ± 2.0 mmHg versus 36.7 ± 3.5 mmHg, P < 0.05).  
Addition of NAC increased the L-NAME-induced rise in foetoplacental arterial pressure 
to 36.4 ± 3.4 mmHg in preeclamptic pregnancies (P < 0.05) and to 49.2 ± 2.6 mmHg 
in controls (P<0.05) .  
Preeclampsia is associated with a dysfunction of the NO pathway. N-acetylcysteine 
increases NO-mediated effects in the foetoplacental circulation in preeclamptic 
placentae as well as in healthy controls. 
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INTRODUCTION 
 
 
Preeclampsia, a major complication of pregnancy, is associated with endothelial 
dysfunction in the maternal and foetal circulation. In this disease, there is probably an 
increase in oxidants, such as reactive oxygen species (ROS) [1;2] and increased lipid 
peroxidation as well as a decrease in several antioxidants, such as α-tocopherol β-
carotene, ascorbic acid and gluthation [3-5]. This dysbalance may be responsible for 
the observed endothelial dysfunction. Recently, vitamin C and E supplementation to 
women with an increased risk for preeclampsia was shown beneficial in prevention of 
this disorder [6]. 
An optimal placental vascular function is important for normal foetal growth and well-
being. Since the placenta lacks autonomic innervation, locally produced mediators like 
the endothelium derived relaxing factor nitric oxide (NO) play an important role in the 
maintenance of normal foetoplacental blood flow. NO is synthesized by the enzyme 
NO-synthase (NOS) in the endothelial cell, after stimulation by various factors (like e.g. 
shear stress, serotonin, bradykinin). NO diffuses to the vascular smooth muscle cell, 
where it activates the guanylate cyclase to increase intracellular cGMP.  This is 
followed by a closure of calcium channels, a fall in intracellular calcium and a 
subsequent relaxation of the vessel wall.  
NO is inactivated by ROS resulting in the formation of peroxynitrite. As such, an 
increase in ROS in preeclampsia might induce dysfunction of the NO pathway in the 
foetoplacental arterial circulation. In the present study we tried to investigate whether 
the antioxidant substance N-acetylsteine (NAC) is able to affect the NO pathway. NAC 
is a pharmacological substance, which is rapidly deacetylated into cysteine, a direct 
precursor of gluthation. Whole blood gluthation concentrations were shown to increase 
after NAC administration to healthy, non-pregnant women [7]. Short-term intra-arterially 
administered gluthation improves endothelial function in the femoral circulation in 
patients with arteriosclerosis [8]. Apart from the indirect protection against ROS, being 
a precursor of gluthation, N-acetylcysteine itself is able to scavenge ROS by 
nonenzymatic reductions [9]. 
 
Along this line of reasoning, we hypothesize that administration of NAC in the 
foetoplacental vascular bed might improve endothelial function, especially that 
mediated by the NO pathway, in the placenta from women with preeclampsia. To 
address this, we investigated the effect on the NO pathway of acute administration of 
NAC in the foetoplacental vascular bed of placentae from women with mild 
preeclampsia as compared to placentae from healthy pregnant control women.   
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METHODS 
 
 
The Medical Ethical Review Committee approved the experimental protocol, and each 
subject gave written informed consent. 
 
 
Study population 
Pregnant women with mild preeclampsia were eligible to participate in this study. Mild 
preeclampsia was defined as a diastolic blood pressure > 90 mmHg measured at least 
two times with an interval of 4 hours, in combination with proteinuria defined as a 
protein/creatinine ratio > 30 mg/mmol, according to the criteria of the International 
Society for the Study of Hypertension in Pregnancy. Controls were healthy women 
after uncomplicated, normotensive pregnancy. Exclusion criteria were diabetes mellitus, 
multiple pregnancy, premature birth (<37 weeks gestation), foetal growth retardation, 
retained placenta, and HELLP syndrome (hemolysis, elevated liver enzymes and low 
platelets).  
 
 
Placenta perfusion  
Placentae were obtained immediately following delivery. Within 15 minutes, two 
suitable cotyledons were selected for ex-vivo dual perfusion [10]. Perfusion of both 
these cotyledons was performed simultaneously on two identical perfusion devices. The 
third or fourth order artery and vein were cannulated just before passage through the 
chorionic plate. Foetal inflow was gradually increased to 6 ml/min, at which the 
baseline foetoplacental arterial pressure equilibrates between 15 to 40 mmHg. The 
cotyledon was placed in a chamber with the maternal side facing upward. Maternal 
inflow was kept constant at 12 ml/min. The maternal outflow was collected and 
returned into the maternal reservoir. A recirculating system was used for both foetal 
and maternal side. The perfusion fluid (Krebs-Henseleit buffer without albumin, pH 7.4: 
150 ml for both sides) was 37°C, and was oxygenated with 95% O2 and 5% CO2.  
Because the foetal arterial inflow was kept constant, the foetoplacental arterial pressure 
was considered to be a reflection of the foetoplacental arterial resistance. After 30 
minutes of equilibration, when the remnant blood had been washed out and the 
foetoplacental arterial pressure was stabilised, the experiment was started. The NO-
mediated component of baseline vascular tone in the foetal circulation was investigated 
by addition of the specific NO-synthase blocker L-NAME over a concentration range 
from 1 to 500 µM in a cumulative way. L-NAME was added to the foetal circulation in 
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six dosages. After each addition stabilization of the foetoplacental arterial pressure was 
awaited, which took maximally 30 min, before we added the next dose. Fifteen 
minutes prior to the first dose of L-NAME, NAC was dissolved in the Krebs Henseleit 
buffer (KH buffer) in one of the perfusion devices, to a final circulating concentration of 
50 µmol/L, whereas KH buffer with no additives (placebo) was added in the other 
device. 
 
 
Materials 
A KH buffer containing 121 mM NaCl, 4 mM KCl, 0.95 mM KH2PO4, 1.2 mM MgSO4-
7H2O, 22 mM NaHCO3, 11.1 mM glucose-H2O, and 2 mM CaCl2 was used as perfusion 
fluid. Heparin was used in a concentration that does not affect vascular tone (2500 
IE/L) [11]. L-NAME and N-acetylcysteine were obtained from Sigma (St. Louis, USA). 
The NAC concentration in the perfusion fluid (50 µmol/L) was based on the plasma 
levels in a clinical study of healthy volunteers who received 3 x 1800 mg N-
acetylcysteine daily. The median plasma level of N-acetylcysteine after three gifts of 
NAC was 48 µmol/L (range 37 - 71 µmol/L). 
 
 
Statistical analysis  
Comparison of the clinical characteristics was performed by a Mann-Whitney U test. 
Data on perfusion pressures were analysed using Prism 3.0 (Graphpad Software) by 
fitting individual concentration-response curves for each experiment. For each 
experiment, the curve characteristics were calculated. These were baseline 
foetoplacental arterial pressure, maximum L-NAME-induced foetoplacental arterial 
pressure, net L-NAME-induced increase in foetoplacental arterial pressure, and logEC50. 
For differences between groups these curve characteristics were compared by two-way 
ANOVA, with group (control or preeclampsia) and medication (vehicle or NAC) as 
independent factors. Differences were considered to be statistically significant when 
zero was not included in the 95 % confidence interval. 
 
 
 
RESULTS 
 
 
Clinical characteristics 
Apart from the expected differences in diastolic blood pressure and proteinuria, there 
were no statistically significant differences in clinical characteristics between the two 
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groups (Table 1). In the control group one patient used vitamin B12, in the 
preeclampsia group one patient used the low molecular weight heparin nadroparine 
(thrombosis profylaxis) and one used methyldopa. 
 
 
Table 1 
Clinical characteristics  
 Control Preeclampsia 
Number 8 8 
Maternal age (years) 31.7 (28.2 – 38.0) 27.9 (26.3 – 41.3) 
Parity (n) 1 (0 – 3) 0 (0 – 3) 
Gestational age (weeks) 39.5 (38.0 – 41.1) 39.1  (37.6 – 39.6) 
Birth weight (grams) 3757 (2610 – 3990) 3175 (2745 – 4035) 
Placental weight (grams) 595 (410 – 755) 582 (390 – 790) 
Body Mass Index (kg/m2) 21.7 (18.9 – 28.8) 27.5 (19.4 – 43.6) 
Diastolic blood pressure (mmHg) 77.5 (75.0 – 85.0) 98.0 (90.0 – 110.0) ∗ 
Caesarean section (n) 1 1 
Smokers (number) 1 0 
Protein/creatinine ratio (g/10 mmol) n.m  1.15 (0.59 – 3.38) ∗ 
Data are given as medians (min-max) or numbers  
∗ = P < 0.05 
n.m.: dipstick negative in all women 
 
 
 
Effects of L-NAME in isolated cotyledons  
Two cotyledons of 8 placentae from women with uncomplicated pregnancies and of 8 
from women with mild preeclampsia were perfused. The concentration-response curves 
for L-NAME are presented in Figure 1.  
Baseline foetoplacental arterial pressure was comparable in all groups (Table 2). L-
NAME elicited a concentration-dependent rise in foetoplacental arterial pressure. 
Maximum L-NAME-induced foetoplacental arterial pressure in the placentae from 
healthy controls was 60.5 ± 3.1 mmHg (mean ± SEM). The absolute L-NAME-induced 
rise in foetoplacental arterial pressure was 36.7 ± 3.5 mmHg.  
In preeclampsia, the maximum L-NAME-induced foetoplacental arterial pressure was 
45.6 ± 4.5 mmHg. The absolute L-NAME-induced increase in foetoplacental arterial 
 92
 CHAPTER 6
pressure was 20.8 ± 2.0 mmHg (P <0.05 as compared to controls). There was no 
difference in logEC50 values between the groups. 
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Figure1 
L-NAME-induced rise in foetoplacental arterial pressure in healthy controls without (□) 
and with (■) addition of N-acetylcysteine, and preeclampsia without (○) and with (●) N-
acetylcysteine. The horizontal dottet line shows that after NAC the net foetoplacental 
arterial pressure in preeclampsia is comparable to that in the placenta of healthy 
controls without NAC. 
 
 
Effects of NAC 
Addition of NAC did not significantly affect baseline foetoplacental arterial pressure. 
After addition of NAC, the maximum L-NAME-induced foetoplacental arterial pressure 
was 72.2 ± 5.6 mmHg in the placentae of healthy controls and 59.4 ± 6.7 mmHg in 
preeclampsia. The absolute L-NAME-induced increase in foetoplacental arterial pressure 
was 49.2 ± 2.6 mmHg in controls and 36.4 ± 3.4 mmHg in preeclampsia.  This NAC-
effect reached statistical significance in healthy controls (P<0.05) as well as in 
preeclampsia (P<0.05). 
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DISCUSSION 
 
The two main observations of our study are that 1) the contribution of NO to baseline 
vascular tone is impaired in the foetoplacental circulation of preeclamptic patients, and 
2) the NO-mediated effects can be ameliorated to normal levels by addition of the anti-
oxidant N-acetylcysteine.  
 
 
Table 2 
Characteristics of the fitted concentration-response curves of the NOS inhibitor L-
NAME 
 Control Control Preeclampsia Preeclampsia 
Number of experiments 8 8 8 8 
Baseline FAP (mmHg) 23.7 (2.8)  23.0 (3.6) 24.8 (2.7) 23.0 (2.5) 
Maximal FAP (mmHg) 60.5 (3.1) 72.2 (5.6) 45.6 (4.5)  59.4 (6.7) 
∆ L-NAME-induced increase  
                in FAP (mmHg) 
36.7 (3.5) 49.2 (2.6) # 20.8 (2.0) ∗ 36.4 (3.4) # 
Log EC 50 (logM) -4.7 (0.1) -4.9 (0.1) -4.5 (0.1) -4.5 (0.1) 
Statistical comparison by two-way ANOVA, with group (control or preeclampsia) and 
medication (vehicle or NAC) as independent factors. Data are presented as mean ± 
SEM.  FAP = Foetoplacental Arterial Pressure 
∗ P < 0.05 versus controls without NAC  
# P < 0.05 versus corresponding group without addition of NAC  
 
 
Our conclusions on the NO pathway are based on the quantitive assessment of the 
vasoconstrictor response to the NO-synthase inhibitor L-NAME. This is an indirect 
measure of the functional vasodilator effect of NO in this specific vascular bed. An  
attenuated vasoconstrictor response to L-NAME can be interpreted as a reduced effect 
of functional NO in the circulation. In a previous study, we already reported on 
an impaired effect of NO in the placenta of preeclamptic patients [12]. This reduced NO 
pathway in the foetoplacental vascular bed in preeclampsia is expected to be 
associated with an increase in baseline foetoplacental arterial pressure. In our study, 
however, we did not observe a difference in baseline foetoplacental arterial pressure 
between patients with preeclampsia and the healthy controls. Nevertheless, we did 
observe a significantly decreased response to L-NAME in preeclampsia, which proves 
that the NO pathway is impaired in this vascular bed in these patients. Other 
vasodilator mechanisms might be compensating for the dysfunction of the NO pathway 
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in preeclampsia. Candidates for these compensatory mechanisms are an increased 
release of prostacycline or endothelium-derived hyperpolarizing factor (EDHF) on the 
one hand, and a reduced release of endothelin or vasoconstrictor prostanoids on the 
other hand. This kind of compensation has also been observed in other vascular beds 
with dysfunction of the NO pathway [13;14]. Additional experiments with the 
combined blockade of the aforementioned mechanisms are necessary to be sure 
whether this line of reasoning is correct.  
Other investigators have shown a decrease of NO-products in the urine of preeclamptic 
patients [15]. Of course, urinary NO-products reflect tubular or renal NO-production 
and/or secretion rather than indicating levels of NO in the foetoplacental circulation. 
Interestingly, two independent research groups reported an increase rather than a 
reduction in NO-products in uteroplacental and foetoplacental plasma or serum of 
preeclamptic women as compared to control pregnancies [16;17]. This increase in NO-
products has been attributed to a compensatory mechanism to offset the impaired 
placental perfusion, as frequently observed in preeclampsia [17]. The observations in 
our study can still be compatible with the reports on increased levels of NO-products in 
the preeclamptic placenta, because we quantified the vascular effects of NO, and not 
the concentrationsof NO itself, whereas functional effects of NO can be impaired 
because of a lower responsiveness of the tissue, or due to mechanisms that inactivate 
NO, like oxidative stress.  
The increase in foetoplacental arterial pressure in response to L-NAME could also be 
attributed to an excessive production of a vasoconstricting mediator. L-NAME, 
however, is a specific blocker of the endothelial NO-synthase (eNOS). As such, the 
change in foetoplacental arterial pressure somehow must be mediated by the NO 
pathway. Of course, the observed increase in foetoplacental arterial pressure may be an 
indirect effect of NO, since there is much interaction between the NO pathway and 
other endothelium mediated mechanisms, like the production of endothelins, and 
prostanoids. This implies that the decreased vasoconstrictor response to L-NAME in the 
foetoplacental vascular bed in preeclampsia could also be attributed to diminished 
effects of vasoconstricting mediators. 
In addition, alterations of vascular structure could play a role in the observed functional 
differences between the foetoplacental vascular bed from patients with preeclampsia as 
compared to healthy controls. On average, however, we did not observe a difference in 
baseline pressure between preeclampsia and the control group. Since perfusion flow, 
vessel length, and viscosity of the perfusion flow were similar, we can conclude from 
Poisseuille’s Law that the diameters should be similar in both groups. As such, 
differences in structure of the vessels do not seem to be the underlying cause of the 
observed functional differences between preeclampsia and controls. 
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The addition of N-acetylcysteine positively affected NO-dependent vasodilation in our 
model. As such a decrease in baseline foetoplacental arterial pressure would have been 
expected after addition of NAC. In our study, however, baseline foetoplacental arterial 
pressure was not affected by NAC. Again, this lack of a vasodilator effect of NAC can 
be explained by the putative activation of compensatory mechanisms. Additionally, we 
have to assume that during the subsequent administration of L-NAME the reductions in 
the NO pathway are so large that these cannot be compensated for by the 
aforementioned mechanisms. 
The effect of NAC on the NO pathway could be explained in different ways. At first, 
NAC has antioxidant properties, and has the ability to scavenge reactive oxygen 
species [18]. In preeclampsia, oxidative stress is a mediator of endothelial cell 
dysfunction through the excess of superoxide anion and other free radicals. Superoxide 
may have a direct vasoconstrictor effect on the vasculature or it may react with NO to 
produce peroxynitrite. Myatt and co-workers demonstrated the presence of 
nitrotyrosine residues in placental tissue of preeclamptic pregnancies, indicating the 
presence of peroxynitrite [19]. Thus the availability of NO to act as a vasorelaxant may 
be reduced, directly resulting in vasoconstriction [20]. Addition of NAC to the perfusion 
fluid may result in scavenging of superoxide anions and possibly other reactive oxygen 
species, leading to an increased availability of NO, resulting in NO-mediated 
vasodilatation [21].  
Secondly, it is important to realise that NO can easily react with albumin to form S-NO-
albumin, which is the predominant form of NO in plasma and is an efficient NO 
transporter to the smooth muscle cells of the vessels. NAC, being an aminothiol, might 
compete for NO with albumin (by transnitrosation) and thus may cause decreased 
availability of S-NO-albumin [22]. However, in the KH buffer we used during the 
perfusion experiments, no albumin was added and therefore this protein was not 
available for the formation of S-NO-albumin.  
In addition, N-acetylcysteine is rapidly deacetylated to cysteine, which is the key 
substrate in gluthation synthesis. Gluthation, one of the most important intracellular 
thiols, enhances the bioavailability of NO by forming a stable, biologically active S-
nitrosoglutathion adduct, as described in a group of patients with arteriosclerosis or risk 
factors for arteriosclerosis [23]. Moreover, also the sulfhydryl groups of N-
acetylcysteine and cysteine will bind to nitric oxide resulting in formation of S-
nitrosothiols, a stored form of nitric oxide. The S-nitrosothiol compounds activate the 
guanylate cyclase enzyme causing vasodilatation [24]. We do not think that the latter 
mechanism was operative in our model because we did not observe a vasodilator effect 
of NAC alone on baseline vascular tone in the foetoplacental circulation.  
In theory, the vasodilator effect could also be independent from NO. Due to addition of 
N-acetylcysteine in the perfusion fluid an excess of free sulfhydryl groups is present, 
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which could result in their auto-oxidation, with subsequent formation of superoxide and 
hydrogen peroxide. This may directly lead to a vasoconstrictor response or indirectly 
through the formation of peroxynitrite. Again, this is not plausible because we did not 
observe an increase in foetoplacental arterial pressure during our perfusion experiments 
after addition of NAC.  
 
Our results do not necessarily mean that oral NAC-treatment of preeclamptic women 
will have comparable effects on the foetoplacental circulation as described here in the 
ex vivo system. First, in vivo there may be an equilibrium between free and bound 
NAC, due to disulphide bonds [9]. In this ex vivo study, the availability of free NAC (-
SH) probably is higher as compared to the in vivo situation, because the perfusion fluid 
does not contain proteins, although we realise that NAC may be auto-oxidied. 
Additionally, a dose-response study to estimate the optimal dose for clinical use has not 
been performed yet. In vivo, over 80 % of NAC is bound to plasma and tissue proteins 
by labile sulphide bonds [9], and is therefore not available for scavenging of ROS. 
Further, the present study describes the effects of short-term administration of NAC to 
the perfusion buffer, resulting in an increase in the vasoconstrictor response to L-
NAME. This was in concordance with other studies regarding vascular function after 
administration of an antioxidant [8;12]. Various studies showed anti-oxidant 
biochemical effects of NAC without investigating vascular function [6;7;21]. N-
acetylcysteine is transported across the placenta, suggesting that maternal NAC 
supplementation might reach the foetoplacental endothelium [25]. However, the effect 
on the foetoplacental vascular function of long-term maternal NAC administration 
remains unknown. 
 
In conclusion, ex vivo the contribution of NO to the baseline vascular tone is impaired 
in the foetoplacental circulation from preeclamptic patients. Moreover, the NO pathway 
can be ameliorated  by addition of the anti-oxidant N-acetylcysteine to the perfusion 
buffer.  
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PLACENTAL UPTAKE AND BINDING OF 5MTF IN FOETAL GROWTH RESTRICTION 
SUMMARY  
 
Maternal folate deficiency is associated with foetal growth restriction, however, 
transfer of folate across placentae from pregnancies complicated by foetal growth 
restriction has never been investigated. We studied whether maternal to foetal 5-
methyltetrahydrofolate (5MTF) transport in the ex vivo dually perfused isolated 
cotyledon, binding of [3H] folate (PteGlu) to the syncytial microvillous membrane, and 
protein expression of folate receptor-α (FRα) and reduced folate carrier (RFC) in these 
placentae are disturbed.  
Placental clearance of 5MTF from the maternal perfusate appeared to be non-saturable 
over a range of 50 to 500 nM, independent of albumin and flow-independent. No 
statistically significant differences between placentae complicated with foetal growth 
restriction and uncomplicated pregnancies were observed. Binding characteristics of 
[3H-]PteGlu to microvillous membranes of foetal growth restriction versus control 
placentae were similar: Bmax of 3.9 ± 2.0 (mean ± SD) versus 4.0 ± 1.6 pmol/mg protein 
and a Kd of 0.037 ± 0.010 versus 0.040 ± 0.018 nM. Expression of FRα and RFC were 
not different in placentae of both groups studied.  
In conclusion, foetal growth restriction appears not to be associated with impaired 
maternal to foetoplacental folate transport, placental receptor binding, or expression of 
FRα and RFC. 
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INTRODUCTION 
 
Folate is an essential micronutrient for human beings, because of its role in a number of 
intracellular processes resulting in cell growth. Especially during pregnancy, an optimal 
placental uptake of folate from the maternal circulation is critical for development and 
growth of the placenta and an adequate supply of folate to the developing foetus. 
Maternal folate deficiency is associated with various complications of pregnancy under 
which a low birth weight [1-6].  
The exact mechanism of maternal-to-foetal folate transport is still not completely 
elucidated. The initial uptake step in placental folate transfer most likely involves 
endocytosis mediated by the folate receptor-α (FRα) at the microvillous membrane of 
the syncytiotrophoblast. FRα is a glycosylphosphatidylinositol-anchored protein located 
at the microvillous membrane. This receptor is in direct contact with the maternal blood 
and binds folates with high affinity in the low nanomolar range [7-10].  
On the basolateral side of the syncytiotrophoblast, folate efflux into the foetal blood is 
facilitated by the reduced folate carrier (RFC), which is driven by the transmembrane 
H+-gradient [11;12].  
To our knowledge only one study on the kinetics of folate uptake in isolated human 
perfused placenta has been published [13]. Despite the low dissociation constant, 
placental uptake appeared not to be saturable at folate concentrations up to 1000 nM. 
No study has been performed yet on folate transport in placentae from pregnancies 
complicated by foetal growth restriction. During pregnancy, marginal availability of 
folate to the placenta or foetus can impair normal cellular growth and replication. This 
may arise from low folate intake or deficient placental uptake and subsequent transfer 
to the foetal blood.   
The aim of this study was to investigate whether there is a difference in folate binding 
and transfer between placentae from healthy controls and those from foetal growth 
restriction. 
  
 
 
METHOD 
 
 
Study populations 
All pregnant women with uncomplicated pregnancies were eligible to participate in this 
study. Foetal growth restriction was diagnosed if the foetal abdominal 
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Table 1  
Patient characteristics  
 Foetal growth restriction Control 
Number 10 50 
Maternal age (years) 28.3 (22.3 – 37.9) 32.9 (20.8 – 42.1) 
Parity (number) 0 (0 - 2) 1 (0 - 4) 
Gestation (days amenorrhoea) 267 (257 - 287) 276 (259 - 297) 
Birth weight (grams) 2095 (749 - 2575) ∗ 3375 (2375 - 4650) 
Placental weight (grams) 400 (200 - 635) ∗ 593 (350 - 1110) 
Gender child (number of boys (%)) 5 (50%) 24 (48%) 
Body Mass Index (kg/m2) 20.7 (17.7 – 25.5) 22.9 (18.3 – 34.0) 
Diastolic BP (mm Hg) 75.0 (70.0 – 90.0) 70.0 (40.0 – 90.0) 
Caesarean section (number (%)) 4 (40%) 16 (32%) 
Smokers (number (%)) 3 (30%) 9 (18%) 
Alcohol (number) 0 0 
Medication  (number) Oxazepam (1) Iron (3) 
Periconceptual folic acid use (number (%)) 5 (50%) 24 (48%) 
Maternal serum folic acid (nmol/L) 18.0 (8.4 – 27.4) 12.4 (6.7 – 32.0) 
Umbilical venous serum folic acid (nmol/L) 45.7 (5.9 – 65.7) 28.8 (9.3 – 40.7) 
Maternal erythrocyte folic acid (nmol/L) 896 (311 - 1595) 844 (213 - 1474) 
Umbilical venous erythrocyte folic acid 1728 (311 - 3448) 1254 (566 - 1818) 
Data presented as median and range, ∗ P < 0.05 versus healthy controls. 
 
 
Table 2  
Kinetic parameters characterising placental 5-methylTHF disappearance from the 
maternal perfusate of the ex vivo isolated perfused cotyledon of foetal growth 
restriction versus control 
 Control Foetal growth restriction 
t1/2α (min) 10.2  (4.2)  4.4 (1.2)  
t1/2β (min) 209 (47)  388 (95) 
Co (nM) 173 (17) 155 (23) 
CL (ml/min) 0.90 (0.44) 1.32 (0.79) 
Values are presented as mean (SEM)
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circumference was below P10 on two following occasions, and growth had followed a 
curve within the normal ranges for the Dutch population during a longer period of 
pregnancy, until this deviation had been observed. Exclusion criteria for both groups 
were an intrauterine infection, a congenital abnormality, an abnormal umbilical 
pulsatility index [14] and/or cardiotocogram abnormalities prior to labour, multiple 
pregnancy, premature birth (<37 weeks amenorrhoea), retained placenta, pregnancy-
induced hypertension (diastolic pressure >90 mmHg on two following occasions), 
preeclampsia and HELLP syndrome (hemolysis, elevated liver enzymes and low 
platelets).  
Twenty-eight placentae from women with uncomplicated pregnancies were used to 
study the kinetics of  5MTF foetal to maternal transfer. Twenty-two placentae from 
women with uncomplicated pregnancies were used as a control in the comparison with 
10 placentae from pregnancies complicated with foetal growth restriction. Fifteen 
minutes after delivery maternal and umbilical venous blood samples for serum and 
erythrocyte folate determination were taken. The clinical characteristics as presented in 
table 1 were obtained from medical records. All women gave their written informed 
consent. The medical ethics committee of the University Medical Centre approved this 
study. 
 
 
Placenta perfusion  
Ex vivo placental perfusion was performed as described before [15]. Antipyrine (0.43 
mM) was used as a diffusion marker and was measured in perfusate according to 
Brodie et al. [16].  If more than 10 % perfusion fluid had disappeared, after correction 
for loss due to sampling, the experiment was discarded. To avoid photodecomposition 
of 5MTF, the experiments were performed in subdued daylight. 
Dose-dependent transport in control placentae was studied by administering one dose 
of 5MTF into the maternal perfusate at t = 0 min to a final concentration varying from 
0 to 500 nM. Samples of both foetal and maternal fluid were collected in dark reaction 
tubes containing 1% (w/v) of ascorbic acid to stabilize the 5MTF, immediately frozen in 
liquid nitrogen, and stored at -80°C until further assay. In addition, the influence of 
increased maternal flow (20 ml/min) and albumin binding  (1.8 g/L) on placental folate 
uptake were investigated a concentration of 100 nM 5MTF.  5MTF was measured in 
maternal and foetal perfusion fluid by HPLC with fluorescence detection (details 
available upon request).  
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Isolation of syncytial microvillous membranes 
Syncytial microvillous membranes were isolated from human term placentae from 
uncomplicated pregnancies (n=8) and from placentae from pregnancies with foetal 
growth restriction (n=4) according to method 3 as described by Glazier, Jones and 
Sibley [17], with some modifications as described by Van der Aa et al. [18]. To 
determine the purity of the microvillous membrane suspension, alkaline phosphatase 
was analysed in the starting mince and final suspension according to Mircheff and 
Wright [19]. Alkaline phosphatase had to be enriched at least 9 times, otherwise the 
material was not used.  
 
 
Binding of [3H]PteGlu to MMV
The microvillous membrane suspension was diluted in Krebs Henseleit phosphate 
buffer, pH 7.4 (KH buffer) to a protein concentration of 4 µg/ml. Each assay was run in 
triplicate at 37°C.  A solution of 100 µl  [3H]folate ([3H ]PteGlu) in KH buffer and 150 µl 
KH buffer were transferred into glass test tubes (4 ml) in a concentration range of 
[3H]PteGlu from 0.02 to 1.70 nM. At t=0, 250 µl membrane suspension was added to 
a final concentration of 2 µg/ml protein and a final concentration range of [3H]PteGlu 
from 0.01 to 0.85 nM. In a second set of tubes at the three highest concentrations of 
[3H] PteGlu 150 µl 60.0 µM PteGlu in KH instead of KH was transferred to analyse the 
non-specific binding. The test tubes were vortexed and placed in a water bath of 37°C 
and incubated for 90 minutes. Incubations were stopped by adding 2.0 ml ice-cold KH 
buffer, immediately followed by vacuum filtration over a Whatman GF/F glass fibre filter 
(Whatman, Kent, UK). Every filter was washed three times with 5.0 ml ice-cold KH 
buffer to remove unbound [3H]PteGlu. Filters were put in vials containing 4.0 ml 
Aqualuma scintillation fluid (Lumac, Groningen, the Netherlands) and radioactivity 
retained on the filters was counted in a Beckman LS 6000 LL scintillation counter. 
 
 
Immunoblot analysis of FRα and Reduced Folate Carrier  
Western Blot analysis was performed on microvillous membrane fractions and crude 
mince for FRα, and on crude mince for RFC. For RFC only crude mince was used, 
because we did not have enough material left to isolate a basal membrane fraction as 
well. The immunoblot analysis was performed as described before for RFC [20]. To 
detect FRα proteins the same procedure was used with MOv-18 as primary antibody 
(Alexis Biochemicals, Montreal, Canada) followed by horseradish peroxidase conjugated 
goat anti mouse IgG as secundary antibody (Sigma Immunochemicals, St. Louis MO, 
USA). Intensities of bands were measured using Scion Image Release Beta 3b (1998) 
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(www.scorpioncorp.com). The average pixel intensity for each placenta was calculated 
and averaged for the 8 placentae from healthy controls and for the 4 placentae from 
foetal growth restriction.   
 
 
Materials 
Perfusion fluid consisted of a KH buffer containing 121 mM NaCl, 4 mM KCl, 0.95 mM, 
KH2PO4, 1.2 mM MgSO4, 20 mM NaHCO3, 11.1 mM glucose, 2 mM CaCl2 and 2500 
IE/L heparin. Antipyrine, 5MTF, and PteGlu were obtained from Sigma (St. Louis, USA), 
ascorbic acid from Merck (Darmstadt), [3H]PteGlu  from Amersham (Buckinghamshire, 
UK).  
 
 
Statistical analysis 
Data were analysed by curve fitting of individual experiments using Prism 3.0 
(Graphpad Software), Patient and placenta characteristics were compared using Mann 
Whitney U test or Fisher’s Exact test when appropriate (SPSS 10.0). 
 
 
 
RESULTS 
 
 
Patient characteristics 
Placentae from 60 women were investigated. The clinical characteristics are presented 
in table 1. Apart from foetal and placental weight, patient characteristics, including 
serum and erythrocyte folate, were comparable.   
 
 
Kinetics of 5MTF disappearance from maternal perfusate 
The kinetics of 5MTF disappearance from maternal perfusate at an initial concentration 
of 100 nM was compared with doses of 50 and 500 nM, and the influence of albumin 
(1.8 g/L) and an increased maternal flow (20 ml/min) was studied. Data of each 
individual experiment were analysed best according to a two-phase exponential decay 
curve. Rate constants alpha (α, initial decay) and beta (β, slow decay) and initial 
concentration (C0) were determined by curve fitting. Kinetic parameters after 100 nM 
(n=5) were, alpha half-life (t1/2α) = 7.3 + 2.6 min, beta half-life (t1/2β) = 530 + 70 
min, and clearance (Cl) = 1.39 + 0.15 ml/min, and were not significantly different 
from 50 (n=4) and 500 nM (n=3) or influenced by albumin (n=3) or an increased 
 109
PLACENTAL UPTAKE AND BINDING OF 5MTF IN FOETAL GROWTH RESTRICTION 
maternal inflow (n=5). Appearance of 5MTF in the foetal perfusate increased with the 
concentration in maternal perfusion fluid and was about 6 % of the initial maternal 
concentration. 
 
 
Foetal growth restriction versus uncomplicated pregnancies 
Perfusion of the isolated placental cotyledon 
Fourteen placentae from controls and 6 from foetal growth restriction were used for the 
perfusion experiments. In each experiment 5MTF was added to the maternal perfusion 
buffer in a concentration of 200 nM at t = 0 min. The kinetic parameters did not differ 
between the groups (table 2), and no differences were observed in the percentage of 
the initial maternal concentration that appeared in the foetal perfusate.  
 
spec. bound [3H]PteGlu (pmol/mg protein)
0.0 0.2 0.4 0.6 0.8
0.0
2.5
5.0
 free [3H]PteGlu (nM)
Figure 1 
Binding of [3H]PteGlu to syncytial microvillous membranes of placentae from 
pregnancies complicated by foetal growth restriction (n=4, ∆) and uncomplicated 
pregnancies (n=8, □) 
 
 
Binding of [3H]PteGlu to syncytiotrophoblast microvillous membranes 
Binding to microvillous membranes of 8 placentae from uncomplicated pregnancies was 
compared with those from 4 pregnancies complicated by foetal growth restriction. The 
purity of the preparation was checked by enrichment of alkaline phosphatase, which 
was 10.6 ± 0.4 (mean ± SEM) for the uncomplicated group, versus 12.7 ± 1.7 for the 
foetal growth restriction group. Concentration-dependent binding of [3H]-PteGlu was 
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saturable and could be analysed according to a one-site model with a Bmax of 3.9 ± 2.0 
pmol/mg protein for controls and 4.1 ± 1.6 pmol/mg for foetal growth restriction. The 
Kd was 0.037 ± 0.010 nM and 0.040 ± 0.018 nM, respectively (fig. 1). 
 
 
Figure 2 
Immunoblot analysis of  reduced folate carrier (RFC, upper pannel) and folate receptor-α 
(FRα, lower panel). Proteins (30 µg) were separated on a 10% SDS polyacrylamide gel, 
transferred to a nitrocellulose membrane, and incubated with polyclonal GST-hRFC 
antibody (RFC) or monoclonal MOv-18 antibody (FRα). Proteins were visualized using 
enhanced chemiluminescence. Lanes with placental proteins from foetal growth 
retarded pregnancies are marked with an asterix (∗) 
 
 
 
Immunoblot analysis of FRα and RFC  
The MOv-18 antiserum detected a protein of ~ 44kDa in microvillous membranes of 
placentae from healthy controls as well as in placentae from foetal growth retardation 
(fig. 2), which is in concordance with the weight for FRα found by others [21].  
Pixel intensity imaging resulted in similar intensities for both the RFC protein and the 
FR-α protein in placentae from foetal growth retardation and healthy controls. For RFC, 
the average intensities were 1.40 ± 0.06 (mean ± SEM) in placentae from foetal growth 
retardation versus 1.30 ± 0.05 in placentae from healthy controls. For FRα protein the 
pixel intensities were 1.58 ± 0.17 and 1.52 ± 0.12, respectively. 
Western Blot Analysis for FRα with MOv-18 antibody in the crude mince showed a 
protein of ~ 44 kDa as well, with again pixel intensities that were not different 
between placentae from foetal growth restriction and healthy controls (results not 
shown). 
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Radioligand binding studies showed no difference in binding of folate to the microvillous 
membranes isolated from these placentae, and on Western Blot we found no difference 
between expression of both FRα and RFC between both groups studied. This was 
confirmed at a functional level in the perfused cotyledon, in which no difference in 
transport of 5MTF could be observed between placentae from healthy controls and 
those from foetal growth restriction.  
We found a dissociation constant of 0.04 nM for binding of [3H]PteGlu to its receptor 
on isolated syncytial microvillous membranes. In comparable studies, other authors 
reported higher dissociation constants of 0.9 nM [22], 1.8 nM [8] and 3.0 nM [9]. The 
reason for the discrepancy with our results is not clear. Maybe these authors 
characterized a lower affinity binding site, as they used 30–40 times higher 
concentrations of [3H]PteGlu in their binding assay. For 5MTF, the folate we used 
during the perfusion experiments, the Kd value is much higher and approximately 30 
nM, as derived from competitive inhibition of  [3H]PteGlu binding [22]. This value is in 
the range of physiological 5MTF concentrations and indicate that in our perfusion 
experiments at 200 nM, which is about ten times the serum concentrations following 
optimal folate suppletion [23], virtually all available receptors must have been occupied.  
A disturbed availability of folate could play a role in foetal growth restriction through 
different pathways, including maladaption of the placenta in early pregnancy or 
vascular placental insufficiency. In our study group, vascular placental insufficiency 
was unlikely to be a cause for foetal growth reduction, because cases with an abnormal 
umbilical pulsatility index and/or abnormal cardiotocogram were excluded. Low folates 
in the foetus could be also caused by maternal folate depletion, and a decreased 
transport of folate to the foetus. Foetal folate insufficiency may cause metabolic 
problems leading to an impaired foetal growth. Despite the fact that folate deficiency is 
associated with foetal growth restriction in observational studies(4;5), our observations 
show that in case of pregnancies complicated by foetal growth restriction, appearance 
of 5MTF in the foetal circulation as well as microvillous folate receptor binding and 
expression of FRα and RFC appeared not to be different from that in uncomplicated 
pregnancies. Foetal growth restriction, if due to a folate deficiency, is therefore more 
likely a result of a low supply caused by maternal folate deficiency. Additionally, other 
factors that could influence the rate of folate transfer have been described, like 
increased NO-levels in the retina [24], and a rise in pH in the colonic basal membrane 
[25]. Foetal growth restriction is, however, associated with a decrease in NO in the 
placenta [26]. Furthermore, if the foetus is small for gestation due to a placental 
insufficiency, it is more likely that the pH is decreased rather than increased. Our 
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findings are in line with earlier observations that uptake of 5MTF from the maternal 
circulation in an isolated perfused cotyledon of the human placenta is not saturable and 
not limited by binding to the folate receptor [13], and from the present study we 
conclude that foetal growth restriction is not associated with impaired placental folate 
uptake. 
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CHAPTER 8 
SUMMARY AND DISCUSSION 
 
 
In spite of an optimal control of mother and foetus during pregnancy, the incidence of 
perinatal complications is increased in women with diabetes mellitus. The cause of 
these perinatal complications often remains unclear. Diabetes mellitus type 1 and 
preeclampsia, as well as folate deficiency are pathological conditions that lead to 
vascular (endothelial) dysfunction. As such, foetoplacental vascular dysfunction may 
contribute to the increased prevalence of perinatal complications observed in 
relationship to these maternal diseases. Although the placenta plays a major role in an 
optimal development and growth of the foetus, little is known about foetoplacental 
function in maternal disease. In this thesis the possible relationship between maternal 
diabetes, preeclampsia (part I and II), and foetal growth restriction (part III), and 
placental vascular dysfunction were studied.  
 
 
Part I 
Diabetes is associated with endothelial dysfunction in different vascular beds. 
Regardless of its importance for the development and growth of the unborn child, only 
little is known about the possible changes in the foetoplacental vascular bed in women 
with diabetes. The foetoplacental vascular bed differs from most vascular beds, since 
the placenta lacks autonomic innervation. The vascular function of this organ depends 
on locally available vasoactive mediators. There is evidence from other vascular beds 
that the availability of these mediators may be impaired as a result of diabetes. We 
studied the availability of some of these mediators in the foetoplacental vascular bed 
from women with diabetes mellitus type 1 as compared to healthy controls. In baseline 
conditions the foetoplacental vascular bed is one of low resistance. Therefore, studies 
on mediators causing vasodilation, such as the nitric oxide (NO) pathway and 
endothelium derived hyperpolarizating factor (EDHF) pathway, were performed. In part I 
investigations are presented, which were performed on the NO pathway (chapter 2), 
potassium channels (chapter 3), and the prostanoid pathway (chapter 4). Additionally, 
foetoplacental morphometry, and foetoplacental arterial elasticity were investigated 
(chapter 3).  
Placentae from healthy controls (n=57) and from women with DM (n=30) were 
investigated by ex vivo dual perfusion of the isolated human placental cotyledon. The 
clinical data of these women are presented in table 1. In the total group of women with 
DM baseline foetoplacental arterial pressure was increased as compared to the healthy 
controls (24.5; 17.0 – 40.0 mmHg versus 20.0; 12.0 – 35.5 mmHg, P<0.001 
(median; min - max). This observation, however, was not consistently found within the 
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separate subgroups studied in the chapters 2 to 4, probably due to a type 2 statistical 
error. 
In the nineties of the last century, NO has been identified as an important vasodilatory 
mediator in the placental, and other vascular beds. Diabetes has been associated with 
an impaired vascular endothelial function. Hyperglycaemia reduces the bioavailability of 
NO, whereas hyperinsulinemia increases the endothelial release of NO. In the 
foetoplacental circulation from women with diabetes, hyperglycaemia and 
hyperinsulinemia occur simultaneously. Therefore, the activity of the local NO pathway 
is thought to be different in diabetic women. Because the net effect of these different 
factors is not known, in chapter 2 the contribution of the NO pathway to the regulation 
of baseline vascular tone in the foetoplacental circulation from women with type 1 
diabetes was quantified. Additionally, the influence of short-term administration of 
insulin was investigated in the foetoplacental vascular bed from healthy controls. In 
diabetes an increased contribution of the NO pathway to foetoplacental baseline 
vascular tone was observed, which could not be attributed to the effect of acute 
administration of insulin.  
 
Beside NO, recent studies point towards the EDHF-pathway as having a major 
contribution to the regulation of baseline vascular tone. There is evidence that this 
EDHF pathway is disturbed in diabetes. Unfortunately, the identity of EDHF remains 
unknown. This makes a direct investigation of EDHF difficult. Nevertheless, the open-
state-probability of vascular smooth muscle potassium channels seems to be a final 
common pathway in the mechanism of action. The increased conductance of potassium 
through the potassium channels hyperpolarizes vascular smooth muscle cells, which 
then triggers the closure of voltage-dependent calcium channels resulting in a reduced 
cytosolic calcium concentration and subsequent vasorelaxation. In this thesis not the 
role of EDHF, but the role of different potassium channels in the maintenance of 
baseline foetoplacental arterial tone was studied. A disturbance in the functioning of 
vascular potassium channels may contribute to an impaired endothelial function. In 
chapter 3 the contribution of the KATP, KV, SK, and BK channel was investigated by 
using the same model of ex vivo dual perfusion of the isolated human placental 
cotyledon as described in chapter 2. The results of these studies suggest a contribution 
of both the KATP and the KV channel to baseline tone in the foetoplacental vascular bed 
in healthy controls. In DM, however, the contribution of the KATP channel was impaired. 
Apart from NO and potassium channels, the prostanoid pathway contributes to baseline 
vascular tone. Of all prostanoids, the vasodilator prostacyclin (PGI2), and 
vasoconstrictor thromboxane (TXA) seem to be most important in the regulation of 
vascular function. In diabetes, there is evidence of a disturbed availability and function 
of both these prostanoids. The enzyme cyclooxygenase is a common pathway in the 
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formation of prostanoids. In chapter 4 the net contribution of vasodilator and 
vasoconstrictor prostanoids to baseline vascular tone was investigated by quantification 
of the contribution of the enzyme cycloogygenase to baseline foetoplacental vascular 
tone. Inhibition of cyclooxygenase by indomethacin induced vasoconstriction in the ex 
vivo perfused foetoplacental vascular bed from healthy women. This suggests a more 
important role for vasodilator prostanoids like prostacyclin, than for vasoconstrictor 
prostanoids like thromboxane A2 in this particular vascular bed. In diabetes, the 
vasoconstrictor response to indomethacin was decreased, suggesting a defect in the 
cyclooxygenase pathway in these patients. 
  
Table 1 
Clinical characteristics of the participants  
 Control Diabetes 
Number 57 30 
Maternal age (years) 33.1; 21.1 – 42.8 31.3; 21.0 – 38.2 
Parity (number) 0; 0 - 3 0; 0 - 3 
Gestation (weeks) 39.9; 37.0 – 42.3 38.1; 36.6 – 38.9 ∗ 
Birth weight (grams) 3333; 2500 – 4560 3578; 2435 - 4875 
Placental weight (grams) 570; 370 - 1000 660; 400 – 950 ∗ 
Body Mass Index (kg/m2) 24.2; 15.4 – 30.8 24.0; 17.2 – 51.0  
Diastolic BP (mm Hg) 80.0; 60.0 - 90.0 85.0; 55.0 - 90.0  
Smokers (number ;%) 4; 7.0 2; 6.7 
White Class - 14 B, 9 C, 3 D, 2 F, 2 R 
HbA1c 1st trimester (%)1 - 6.3; 5.0 – 8.8 
HbA1c3rd trimester (%)1 - 6.3; 4.8 - 7.3 
Insulin (mE/ml)     M 21.0; 0.2 – 161.0 28.5; 5.0 – 61.0 
                          U 14.5; 5.0 – 54.0 75.5; 5.0 – 242.0 ∗ 
C-peptide (nmol/l) M 0.98; 0.12 – 2.35 0.13; 0.00 – 0.48 ∗ 
                          U 0.54; 0.21 – 6.00 1.55; 0.28 – 4.16 ∗ 
Baseline foetoplacental arterial pressure 20.0; 12.0 – 35.5 24.5; 17.0 – 40.0 ∗ 
Data are presented as median; min – max, M=maternal, U=umbilical 
∗ P < 0.05 versus healthy controls. 
1normal value for HbA1c in our laboratory is 4.2 – 6.3 %, in pregnant women with DM 
the aim is a value < 7.0 % 
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Other factors, like morphological characteristics and vascular elasticity could contribute 
to baseline vascular tone. Vascular tone is dependent on the diameter, and elasticity of 
the vascular wall of the investigated vascular bed. Studies on morphology of the 
placenta suggest that this organ is morphologically different in diabetes mellitus as 
compared to controls. However, a morphometric analysis of the foetoplacental vascular 
bed has never been performed. Additionally, the effect of diabetes on the elasticity of 
the vascular wall from foetoplacental resistance vessels is unknown. Therefore, 
morphometric parameters as well as vascular elasticity were investigated in the 
foetoplacental vascular bed. No differences in morphometry or elasticity of resistance 
vessels were observed between foetoplacental vascular beds from controls and DM.  
In conclusion, baseline foetoplacental vascular tone is increased in diabetes. This could 
be attributed to impaired function of the KATP channel, and the cyclooxygenase 
pathway. The contribution of the NO pathway, although different from controls, is 
increased in diabetes. In theory, this might be attributed to a compensatory vasoactive 
mechanism in the foetoplacental vascular bed in diabetes.  
 
 
Part II 
Preeclampsia has been associated with endothelial dysfunction, and a subsequent 
impaired availability of NO for vasodilation. The underlying cause might be a disturbed 
balance between oxidants and anti-oxidants, resulting in an increased breakdown of NO 
by reactive oxygen species (ROS). Inactivation of NO by ROS results in the formation of 
peroxynitrite, which is increased in the foetoplacental vascular bed in preeclampsia. 
Supplementation of the antioxidant vitamins C and E to women with an increased risk 
for preeclampsia was shown to be beneficial in the prevention of this disorder. Another 
pharmacological substance with antioxidant capacities is N-acetylcysteine (NAC). NAC 
is rapidly deacetylated into cysteine, a direct precursor of gluthation. Short-term intra-
arterially administered gluthation improves endothelial function. Theoretically, the 
additions of radical scavengers like vitamin C or NAC to the foetoplacental vascular bed 
might be able to improve endothelial function. 
In chapter 5 the contribution of the NO pathway to baseline foetoplacental vascular 
tone was investigated in the foetoplacental vascular bed from women with PE as 
compared to that from controls. In addition, the effect of acute administration of 5 mM 
vitamin C into the foetoplacental circulation on the NO pathway was studied in 
controls. From the results of these studies it could be concluded that the contribution 
of the NO pathway to baseline vascular tone is impaired in the foetoplacental 
circulation from patients with preeclampsia. Vitamin C is able to increase the NO-
mediated vasodilator component in this vascular bed from healthy controls. 
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Apart from vitamin C, the acute effect of N-acetylcysteine (NAC) was studied, as well. 
Chapter 6 describes the results of a study in which NAC was administered in the 
foetoplacental circulation from women with preeclampsia as well as in that from 
healthy controls. For each experiment a simultaneous control experiment was 
performed in a cotyledon from the same placenta, however, with addition of a solvent 
instead of the active substrate. The results from this study confirm the observation 
from chapter 5 that ex vivo the contribution of NO to the baseline vascular tone is 
impaired in the foetoplacental circulation from preeclamptic patients. Moreover, this 
study shows that the NO pathway can be ameliorated by addition of the anti-oxidant N-
acetylcysteine to the perfusion buffer.  
In conclusion, the contribution of the NO pathway to foetoplacental baseline vascular 
tone is decreased in preeclampsia as compared to controls. Acute administration of the 
radical scavengers vitamin C (in controls) and N-acetylcysteine (in controls, and 
preeclamptic patients) into the foetoplacental circulation was beneficial for the 
contribution of the NO pathway to vascular tone in this circulation.  
 
 
Part III 
Folate (vitamin B11) is an essential micronutrient, which plays a major role in a number 
of intracellular processes such as the formation of DNA, and therefore cellular growth. 
An optimal availability of this vitamin is important for normal development and growth 
of the unborn child. Maternal folate deficiency has been associated with a number of 
complications in pregnancy, such as foetal growth restriction. To date, the role of the 
placenta, being the regulating organ for transfer of (micro)nutrients, in foetal growth 
restriction is unclear. Several factors contribute to the availability of folate to the 
foetus. These include the maternal folate supply to the placenta, the uptake of folate by 
the placenta, the amount of folate binding to the folate-receptor, and the expression of 
folate binding proteins in the placenta. 
In chapter 7 we investigated whether foetal growth restriction is associated with a 
disturbed placental folate uptake. Maternal folate uptake during ex vivo dual perfusion 
of an isolated cotyledon, binding of folate to the folate receptor-α (FRα), and expression 
of FRα as well as reduced folate carrier (RFC) were compared between placentae from 
pregnancies complicated with foetal growth restriction and those from healthy controls. 
Placental folate clearance was not different, but because of endogenous folate release 
we had to use supraphysiological concentrations. Most probably, in these experiments 
simple diffusion of folate was the major determinant for maternal folate uptake. This 
may have contributed to the fact that no differences could be observed between 
placentae from pregnancies complicated by foetal growth restriction and those from 
controls. However, the radioligand-binding assay, which was performed with 
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physiological concentrations of folate, did not show differences between those groups, 
either. Moreover, the expression of FRα and RFC was comparable in placentae from 
pregnancies complicated by foetal growth restriction and those from controls. 
In conclusion, foetal growth restriction does not seem to be associated with an 
impaired maternal placental folate uptake. Also, placental folate binding to the FRα, and 
expression of FRα and RFC are comparable between placentae from pregnancies 
complicated with foetal growth restriction and those from controls. 
 
 
 
GENERAL CONCLUSION 
 
 
In this thesis a number of associations were studied between maternal diabetes, 
preeclampsia, and foetal growth restriction on onde hand, and a disturbed 
foetoplacental function on the other hand. In diabetes, baseline foetoplacental vascular 
tone seemed to be increased. This could be the result of a disturbed function of the 
KATP channel, and the enzyme cyclooxygenase. In contrast, the contribution of NO to 
baseline foetoplacental vascular tone seemed to be increased in diabetes. In 
preeclampsia, the disturbance in the NO pathway could be diminished by administration 
of the antioxidants vitamin C and NAC. No relationships between maternal placental 
folate uptake, placental folate receptor binding, as well as expression of FRα and RFC 
and foetal growth restriction could be observed. However, the association between 
folate insufficiency and foetal growth restriction could be the result of other causes 
such as a placental malfunction or a very low maternal folate intake.  
Little information is available about the contribution of other vasoactive mediators such 
as vasoconstrictors and biophysical stimuli in the foetoplacental vascular bed in 
diabetes as well as in preeclampsia, and the effect of addition of antioxidants in 
diabetes. These are interesting questions for future studies. Also, it is interesting to 
investigate whether administration of an antioxidant before and/or during pregnancy in 
women with (a risk of) diseases such as diabetes and preeclampsia, ameliorates the 
foetoplacental vascular endothelial function, and decreases the incidence of perinatal 
complications. If that is the case, antioxidants may play a role in the secondary 
prevention of foetoplacental vascular dysfunction in pregnancies complicated with 
maternal diabetes or pregnancies in women at risk of preeclampsia. 
The newly formed placental vascular bed has a life span limited to a period of only nine 
months, including the period of its development. The conclusions that can be drawn 
from the studies presented in this thesis suggest that during this short period, 
pathologic conditions such as diabetes and preeclampsia can result in foetoplacental 
 124
CHAPTER 8 
vascular dysfunction. Type 1 diabetes mellitus exists before pregnancy, and therefore 
the foetoplacental vascular bed is exposed to both hyperglycaemia and 
hyperinsulinaemia from the onset of its development. Although the foetoplacental 
circulation is different because of its lack of autonomic innervation, it may possess 
functional characteristics similar to other vascular beds in the early stages of diabetes. 
If so, the results as presented in part I suggest that endothelial dysfunction is present 
from the very early stage of diabetes. Therefore, the foetoplacental vascular bed from 
women with diabetes might be a good target for future studies of early vascular 
endothelial dysfunction in diabetes.  
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SAMENVATTING
SAMENVATTING 
VERKLARENDE WOORDENLIJST 
 
 
diabetes mellitus Type 1    suikerziekte Type 1 
endotheel     cellen die de binnenwand van bloedvaten 
     bekleden  
foetoplacentaire vaten    vaten van het kind in de moederkoek 
macrosome kinderen    kinderen met een te hoog geboortegewicht 
voor de duur van de zwangerschap 
perinataal     rond de geboorte  
preeclampsia     zwangerschapsvergiftiging 
prevalentie     frequentie waarin een bepaalde 
aandoening voorkomt in de populatie 
vasoconstrictie    vernauwing van de bloedvaten 
vasorelaxatie    verwijding van de bloedvaten 
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SAMENVATTING 
 
SAMENVATTING EN DISCUSSIE 
 
 
Anno 2004 worden vrouwen met diabetes mellitus zowel voor als tijdens de 
zwangerschap intensief gecontroleerd en begeleid. Desondanks hebben vrouwen met 
diabetes mellitus type 1 een verhoogd risico op complicaties in de zwangerschap in 
vergelijking met gezonde vrouwen. De meest bekende complicaties zijn macrosome 
kinderen en aangeboren afwijkingen. Minder bekend is dat deze groep vrouwen ook een 
hoger risico heeft op het krijgen van een te klein of een doodgeboren kind. De oorzaak 
van deze laatstgenoemde nare complicaties blijft tot op heden meestal onopgehelderd. 
Diabetes mellitus type 1, maar ook preeclampsie en een foliumzuurdeficiëntie zijn 
afwijkingen die kunnen leiden tot abnormaal functioneren van bloedvaten, in het 
bijzonder van het endotheel. Een veranderde functie van de foetoplacentaire bloedvaten 
zou kunnen bijdragen aan de verhoogde prevalentie van perinatale complicaties. Hoewel 
bekend is dat de placenta een belangrijke rol speelt in  de groei en ontwikkeling van de 
foetus, is er weinig bekend over de functie van de placenta, bij moeders met een 
onderliggend lijden. In dit proefschrift werden de relatie tussen maternale diabetes 
mellitus type 1 (deel I), preeclampsie (deelI) en foetale groeivertraging (deel III)  
enerzijds en een verstoorde functie van de placenta anderzijds bestudeerd. In het 
bijzonder werden de effecten van ziekten op het endotheel van het foetoplacentaire 
vaatbed onderzocht.  
 
 
Deel I 
Diabetes mellitus wordt in verband gebracht met een gestoorde endotheelfunctie. Er is 
weinig bekend over de mogelijke gevolgen van diabetes mellitus voor het foetale 
vaatbed van de placenta van vrouwen met deze ziekte. In de meeste vaatbedden wordt 
de vaattonus gereguleerd door een combinatie van de invloed van hormonen, 
biofysische factoren (bijvoorbeeld pH) en het autonome zenuwstelsel. Het vaatbed in de 
placenta bevat echter geen zenuwen en om die reden is dit vaatbed voor zijn regulatie 
afhankelijk van locale mediatoren. In diverse vaatbedden zijn aanwijzingen gevonden 
voor een gestoorde aanwezigheid van deze locale mediatoren onder de invloed van 
diabetes. Wij hebben de effecten van een aantal van deze mediatoren in het 
foetoplacentaire vaatbed van vrouwen met diabetes mellitus type 1 bestudeerd in 
vergelijking met die in gezonde controles. Onder normale omstandigheden heeft het 
foetoplacentaire vaatbed een lage vaatweerstand. In dit proefschrift werden met name 
de mediatoren die de weerstand in het vaatbed laag houden bestudeerd. Deze 
mediatoren zijn als groep bekend onder de naam “endothelium derived relaxing factors”, 
waarvan stikstofmonoxide (NO), endothelium derived hyperpolarizing factor (EDHF) en 
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prostacycline (PGI2) de meest bekende zijn. In het laatste decennium van de vorige 
eeuw is het NO geïdentificeerd als een belangrijke vaatverwijder, zowel in het 
placentaire als in andere vaatbedden. Al langer is bekend dat diabetes kan leiden tot 
een verstoring van de endotheelfunctie. Hyperglycemie verlaagt de beschikbaarheid van 
het NO, terwijl hyperinsulinemie de endotheliale  afgifte van het NO verhoogt. Het 
foetoplacentaire vaatbed van vrouwen met diabetes wordt gelijktijdig blootgesteld aan 
deze beide condities. Om die reden wordt gedacht dat de locale NO-functie anders is in 
patiënten met diabetes mellitus. Het effect van deze factoren op de beschikbaarheid 
van het NO is onbekend. In hoofdstuk 2 werd de bijdrage van NO aan de regulatie van 
de basale vaatweerstand in het foetoplacentaire vaatbed van vrouwen met diabetes 
mellitus type 1 gekwantificeerd. Aanvullend werd dit vaatbed van gezonde vrouwen het 
effect van acute toediening van insuline bestudeerd. Uit deze studies bleek dat bij 
diabetes de bijdrage van het NO aan de basale vaatweerstand was verhoogd, hetgeen 
niet kon worden geweten aan het effect van acute toediening van insuline. 
Naast het NO, lijkt het EDHF een grote rol te spelen in de regulatie van de rusttonus 
van vaten.  Omdat de identiteit van EDHF onzeker is,  is het rechtstreeks bestuderen 
niet mogelijk. Wel is uit eerder onderzoek gebleken dat de openingstoestand van 
verschillende kaliumkanalen in de vasculaire gladde spiercel een rol speelt in het 
werkingsmechanisme van dit EDHF. Een verhoogde doorlaatbaarheid van deze 
kaliumkanalen zorgt voor een verhoogd spanningsverschil over de wand van de gladde 
spiercel. Hierdoor sluiten voltage-afhankelijke calciumkanalen, met als gevolg een 
verlaagde concentratie van calcium in de gladde spiercel met als resultaat vasorelaxatie. 
Met deze kennis werd in dit proefschrift niet de rol van het EDHF zelf, maar die van de 
verschillende kaliumkanalen onderzocht. In hoofdstuk 3 werd de bijdrage van het  KATP, 
KV, SK, and BK kanaal bestudeerd in hetzelfde model dat werd gebruikt in de studie in 
hoofdstuk 2. De resultaten van deze studie suggereren dat het KATP en het KV kanaal 
een rol spelen in de handhaving van de basale vaattonus in het humane foetoplacentaire 
vaatbed in gezonde controles. In dit vaatbed van vrouwen met diabetes was de bijdrage 
van het KATP kanaal echter verminderd ten opzichte van de controlegroep. 
Een derde factor die bijdraagt aan de rusttonus van de vaten is het mechanisme via 
prostanoïden. Van alle prostanoïden lijken het vaatverwijdende prostacycline (PGI2) en 
het vaatvernauwende thromboxane A2 (TXA) het meest belangrijk voor de regulatie van 
de vaattonus. Er zijn aanwijzingen dat de bijdrage van deze prostanoïden gestoord is in 
aanwezigheid van diabetes. Het enzym cyclooxygenase is een enzym dat zowel van 
belang is voor de vorming van PGI2 als voor de vorming van TXA. In hoofdstuk 4 werd 
de bijdrage van dit enzym aan de foetoplacentaire vaattonus bestudeerd door gebruik te 
maken van het ex vivo perfusie model. Remming van het enzym cyclooxygenase door 
middel van de stof indomethacine resulteerde in een stijging van de vaattonus in 
gezonde controles. Dit suggereert dat er in het foetoplacentaire vaatbed een grotere rol 
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is voor vaatverwijdende prostanoïden, waaronder het prostacycline, dan voor 
vaatvernauwende prostanoïden als thromboxane. In vrouwen met diabetes trad minder 
vaatvernauwing op na toediening van indomethacine, hetgeen suggereert dat het 
mechanisme dat loopt via indomethacine is gestoord in de placenta van deze vrouwen. 
Concluderend kan worden gezegd dat de vaattonus in het foetoplacentaire vaatbed is 
verhoogd in vrouwen met diabetes. Mogelijk speelt een gestoorde functie van het KATP 
kanaal en een gestoord mechanisme van cycloogygenase een rol in het ontstaan van 
deze verhoogde basale vaattonus. Ook de bijdrage van het NO is veranderd in diabetes. 
De beschikbaarheid van het NO is echter toegenomen, hetgeen resulteert in 
vasorelaxatie. Theoretisch zou de verhoogde beschikbaarheid van het NO in het 
foetoplacentaire vaatbed in diabetes een compensatiemechanisme kunnen zijn. 
 
Andere, niet-specifieke, factoren zoals morfologische karakteristieken en elasticiteit van 
de vaatwand zijn ook van invloed op de rusttonus van de vaatwand. Er zijn studies die 
suggereren dat er morfologische verschillen bestaan tussen de placenta van vrouwen 
met diabetes en die van gezonde controles. Een morfometrische analyse werd tot op 
heden nog niet verricht in dit vaatbed. Ook werd het effect van diabetes op de 
elasticiteit van de foetale vaten in de placenta niet eerder bestudeerd. Om er zeker van 
te zijn dat de verschillen tussen diabetische vrouwen en controles niet werden 
veroorzaakt door deze non-specifieke factoren, werden morfometrische parameters en 
de elasticiteit van de foetoplacentaire weerstandsvaten bestudeerd. In deze analyses 
werden geen verschillen gevonden tussen placenta’s van gezonde vrouwen en die van 
vrouwen met diabetes mellitus.  
 
In totaal werden in deze drie  studies 57 placenta’s van gezonde vrouwen en 30 van 
vrouwen met diabetes onderzocht. Voor deze studie werd voornamelijk gebruik 
gemaakt van het model van ex vivo tweezijdige perfusie van het geïsoleerde humane 
placentaire cotyledon. In deze totale groep blijkt de foetoplacentaire druk in rust 
verhoogd in de placenta’s van vrouwen met diabetes in vergelijking met die in gezonde 
controles  (24.5; 17.0 – 40.0 mmHg versus 20.0; 12.0 – 35.5 mmHg, P<0.001 
(mediaan; min - max). In de separate studies beschreven in hoofdstuk 3 en 4 bleek dit 
verschil echter niet significant. Mogelijk is dit te wijten aan een type 2 statistische fout.  
 
 
 
Deel II 
Ook preeclampsie word in verband gebracht met een verslechterde functie van het 
endohteel, met als gevolg een verminderde beschikbaarheid van NO voor handhaving 
van de basale vaattonus. De onderliggende oorzaak zou verhoogde afbraak van NO 
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kunnen zijn door reactieve zuurstofdeeltjes (oxidanten). Bij deze afbraak wordt 
peroxynitriet gevormd, een stof waarvan bewezen is dat die de endotheelfunctie 
aantast. De hoeveelheid peroxynitriet is verhoogd in de placenta van vrouwen met 
preeclampsie. Toediening van de vitamines C en E, beiden beschikken over een 
antioxidant werking, aan vrouwen met een verhoogd risico op het ontwikkelen van 
preeclampsie, is gunstig gebleken in de preventie van deze ziekte. Ook N-acetylcysteïne 
(NAC) is een stof met anti-oxidante eigenschappen. Deze stof wordt in het lichaam 
omgezet in cysteïne, een directe voorloper van het anti-oxidant gluthation. Kort-durende 
intra-arteriele toediening van gluthation verbetert de endtoheelfunctie. In theorie zou 
toediening van anti-oxidanten aan het foetoplacentaire vaatbed de endotheelfunctie 
moeten kunnen verbeteren.  
In hoofdstuk 5 werd de bijdrage van het NO aan de basale vaattonus vergeleken in het 
foetoplacentaire vaatbed van controles in vergelijking tot die in hetzelfde vaatbed van 
vrouwen met preeclampsie. Tevens werd het effect van toediening van 5 mM vitamine 
C bestudeerd in een controlegroep.  
Naast vitamine C, is ook het acute effect van NAC bestudeerd. Hoofdstuk 6 beschrijft 
een studie waarin NAC werd toegediend in het foetoplacentaire vaatbed van vrouwen 
met preeclampsie en dat van gezonde controles. Voor elk van deze experimenten werd 
een simultaan experiment uitgevoerd in een identieke opstelling, waarbij een placebo 
werd toegevoegd.  
Conclusie van deze studies is dat de bijdrage van het NO aan de basale vaattonus van 
het foetoplacentaire vaatbed is verminderd in preeclampsie. Acute toediening van anti-
oxidanten als vitamine C (controles) en NAC (controles en preeclampsiepatiënten) was 
gunstig voor de bijdrage van het NO aan de vaattonus in dit vaatbed. 
 
 
Deel III 
Foliumzuur (vitamine B11) is een essentiële voedingsstof, die een grote rol speelt in een 
aantal intracellulaire processen waaronder de vorming van DNA, en dus celgroei. Een 
optimale beschikbaarheid van deze vitamine is van groot belang voor een normale groei 
en ontwikkeling van het ongeboren kind. Een foliumzuurgebrek bij de moeder wordt in 
verband gebracht met verschillende complicaties in de zwangerschap, waaronder een 
foetale groeivertraging. De placenta speelt een belangrijke rol in het transport van 
voedingsstoffen naar het kind. Tot op heden is het onduidelijk of de placenta een rol 
speelt in het verband tussen foliumzuurtekort bij de moeder en een groeivertraging bij 
het kind. Verschillende factoren dragen bij aan de opname van foliumzuur vanuit het 
moederlijke bloed in de placenta. Dit zijn onder andere de maternale aanvoer van 
foliumzuur, de hoeveelheid foliumzuur dat aan de foliumzuurreceptor bindt en de 
expressie van foliumzuurbindende eiwitten in de placenta. 
 132
SAMENVATTING 
 
In hoofdstuk 7 hebben werd  onderzocht of een foetale groeivertraging in verband kan 
worden gebracht met een gestoorde foliumzuuropname in de placenta. De opname van 
foliumzuur tijdens ex vivo perfusie van een geïsoleerd cotyledon, de binding van 
foliumzuur aan de  foliumzuurreceptor-α (FRα) en de expressie van zowel FRα  als de 
reduced foliumzuur carrier (RFC) werden bestudeerd in placenta’s van 
zwangerschappen gecompliceerd door een foetale groeivertraging als in die van 
gezonde zwangerschappen.  
Conclusie van dit onderzoek is dat een foetale groeiachterstand niet lijkt samen te 
hangen met een gestoorde opname van foliumzuur aan de maternale zijde van de 
placenta. Ook de binding van foliumzuur aan de FRα en de expressie van FRα en RFC 
was vergelijkbaar tussen placenta’s van zwangerschappen gecompliceerd door een 
foetale groeivertraging en die van gezonde controles.  
 
 
 
SLOTCONCLUSIE 
 
 
In dit proefschrift werd een aantal verbanden bestudeerd tussen maternale diabetes 
mellitus type 1, preeclampsie en foetale groeivertraging enerzijds en een gestoorde 
functie van de placenta anderzijds. In vrouwen met diabetes mellitus lijkt de basale 
foetoplacentaire vaattonus verhoogd te zijn. Mogelijk is dit het gevolg van een 
gestoorde functie van het KATP kanaal of van het enzym cyclooxygenase. Anderzijds 
blijkt de bijdrage van NO aan de basale foetoplacentaire vaattonus verhoogd te zijn. In 
preeclampsie kon de verminderde bijdrage van het NO worden verbeterd door 
toediening van de anti-oxidanten vitamine C en NAC. Er werd geen relatie gevonden 
tussen foetale groeivertraging enerzijds, en de opname van foliumzuur aan de maternale 
zijde van de placenta, binding van foliumzuur aan de FRα , en de expressie van FRα ,  en 
RFC anderzijds. Deze bevinding sluit overigens niet uit dat een foetale groeivertraging 
het resultaat zou kunnen zijn van andere (placentaire) problemen zoals een algeheel 
slecht functioneren van de placenta of van een veel te lage inname van foliumzuur door 
de moeder. 
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EXTRA
 
 
 A HISTORICAL AND CULTURAL VIEW ON THE HUMAN PLACENTA  
 
 
INTRODUCTION 
 
 
The placenta may be the most important organ for human reproduction. During 
pregnancy it combines functions which will be performed by different organs after 
birth. These include respiration, uptake of nutrients, elimination of waste products, and 
hormone production. The functional part of the placenta conists of an extensive 
vascular network surrounded by one layer of so-called syncytiotrophoblastic cells 
bathing in maternal blood. An optimal placental transport and vascular function is 
important for a normal intrauterine development and growth of the foetus.  
In spite of this important role of the placenta, only limited studies have been performed 
of the degree in which placental dysfunction contributes to the prevalence of perinatal 
morbidity and mortality. Therefore, this organ is an interesting and fascinating subject 
for scientific research. Only during the last century has more knowledge become 
available about placental morphology and placental function.  
In the past, when the function of the placenta was not fully understood by human 
beings, all kinds of mysteries, beliefs, habits and rituals have arisen around the 
placenta. These socio-cultural perceptions of the placenta are at least as fascinating as 
the basic scientific observations. Therefore in this chapter a concise survey is presented 
of these perceptions. Unfortunately, some words or sentences were not translatable 
from Dutch to English. 
 
 
 
THE MEANING AND ORIGIN OF THE WORD “PLACENTA”  
 
 
The meaning of the word placenta, and related words, are presented as follows in the 
“Dikke van Dale” [1]: 
Placenta  1. moederkoek, nageboorte 
2. [biol.] zaadkoek, aanhechting van de zaadknop aan 
het vruchtbeginsel 
 
Placentair [biol.]  De moederkoek betreffend 
 
Placentatie [biol.] De ontwikkeling van de moederkoek 
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The use of the word “placenta” originates from 1559. In this year a man named  
Realdus Columbus (1516-1559) is thought to be the first  person that used this word. 
It is a derivation from the modern Latin words placenta uterina, which mean uterine 
cake (ned.: uterine koek). Moreover, the word was known in ancient Latin (placenta: 
flat cake (ned.: platte koek), and ancient Greek (πλακουντα [plakoenta]: accusativus 
from πλακουις [plakoeis]; flat), as well.  
 
 
 
HISTORY OF THE STUDY OF THE PLACENTA 
 
 
The earliest known representation of the placenta is seen on the frequently reproduced 
palette of King Narmer, a well-preserved palette found at Hierankopolis at the end of 
the 19th century (fig 1), probably dating from between 3500 and 3100 before Christ. 
The uppermost panel on the reverse side shows Narmer in ceremonial procession 
preceded by royal standards; to the right are piled decapitated bodies of his enemies. 
The standard nearest the king has the shape of a bilobate disc with a streamer hanging 
down, and has been interpreted as the king’s placenta and umbilical cord [2], the 
prototype of flags carried into battle with their streamers in red, white and blue. The  
 
 
Figure 1 
Palette of King Narmer 
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 ancient Egypt people believed the placenta was a child’s secret helper or quasi twin, 
since they believed the child was formed in the womb from blood and that the unused 
blood formed the placenta, a reserve of vital material [3]. 
Only during the renaissance, in the early 16th century, was a detailed description given 
of the placenta. However, both Leonardo da Vinci and Vesalius based the placenta in 
their pictures on that of other mammals and therefore they misrepresented it. Leonardo 
da Vinci (1452-1515) showing it to be cotyledonary as in the sheep, Vesalius (1514-
1564) showing it to be of the zonary variety as in the bitch. Vesalius, however, 
corrected this error in the second edition (1555) of his great book. 
Harvey knew that the two blood streams in the placenta must be separate, each stream 
flowing in an opposite direction to the placenta, but he knew nothing about capillary 
vessels and could not explain how the blood passed from arteries to veins through the 
tissue. It was not until the publication of Malpighi about capillaries (1660), that 
anatomical bases for the regional circulation became available. Hereafter John Mayow 
(1643–1679) more adequately described the placenta’s nature. Around these days the 
term cotyledon – originally used by the Greek and Romans – was re-introduced for the 
isolated functional unit of the placenta.  
William Hunter (1718-1783) was the first investigator to give a sophisticated 
description of the human placenta. He and his brother John Hunter (1728 – 1793) 
injected fluid wax into the uterine circulation, which did not appear in the foetal 
circulation. Their finding finally set aside the assumption that there existed 
anastomoses between the maternal and foetal circulation. William Hunter was the first 
to effectively describe the decidua (1774). John Hunter first mentioned the decidua 
basalis. 
The establishment of the knowledge of the development and nature of placental villi 
only took place over many years. Indeed, their structure could not adequately be 
appreciated until the development of the compound microscope. The first convincing 
account of the villi was given by Weber (1832), in an illustration of teased out villi 
under low magnification. By 1880 the basic knowledge of the circulation in the 
intervillous space had been established.  
Langhans (Bern) and Hubrecht (Utrecht) were important investigators, responsible for 
the analysis of the histological nature of the covering of the foetal villi. Hubrecht’s term 
“trophoblast” (1889) – a term he used for the layer of cells in the early embryo that he 
interpreted as a nutritive layer and that does not contribute to the cellular portion of the 
embryo – was applicable to the two layers found by Langhans as the covering of the 
chorionic villi. Various investigators demonstrated the superficial layer to be syncýtial in 
nature. Therefore this superficial layer is now generally known as the 
syncytiotrophoblast. The other layer is known as the cytotrophoblast. 
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Grosser (1873-1951) introduced a histological classification based in part upon the 
assumed biological activity of the placenta, the principle of which depends on the 
number and kind of maternal and foetal tissue layers interposed between the blood of 
the mother and the conceptus. This classification (epithelio-chorial, syndesmo-chorial, 
endothelio-chorial, haemo-chorial, and haemochorio-endothelial)  is nowadays often 
criticised. Electron microscopy has made it clear that the arrangement of the 
trophoblasts is more complicated than suspected from studies with light microscopy, 
on which Grosser’s scheme was based. However, his publications were of great 
importance for the investigators who studied the early development of the placenta. A 
lot of investigators have contributed to unravel this puzzle, but the most important 
basic work was performed by Hertig and Rock (1941). They charted the course for 
later explorers in the field of placentology.  
 
 
 
DIFFERENT RITES AND HABITS AROUND THE WORLD 
 
 
Various qualities and powers have been attributed to the placenta. For this reason all 
kinds of rituals are performed with this special organ after birth. Most of these rituals 
find their origin in one of the three categories burial, consumption, or healing power of 
the placenta. However, differences in these rituals exist all over the world. 
 
 
Lotus birth 
There is no written information dating from before 1974 about this ritual being 
performed by humans. Until 1974 only has it been described in chimpanzees. It seems 
to be a modern habit, named after Claire Lotus Day. She was a midwife, who 
challenged doctors reasons for hasty clamping. The ritual of Lotus Birth is the practice 
of leaving the umbilical cord uncut, so that the baby remains attached to his/her 
placenta until the cord naturally separates at the umbilicus, exactly as a cut cord does, 
at 3 to 10 days after birth. To make sure the placenta dries, it is covered with salt 
and/or spice and wrapped into cloths. This prolonged birth can be seen as a time of 
transition, allowing the baby to slowly and gently let go of his/her attachment to the 
mother’s body.  
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 Burn and burry 
The most common rituals are burial and burning of the placenta. Burial or burying of the 
placenta has been performed all over the world, however, the reason for doing so may 
be different. 
In Alaska, some Indians cremate the placenta, preserving the ashes for ultimate burial 
with those of the child after its death [4].  
In the past, in the Salzburg region in Austria it was customary to bury the placenta 
under a green tree to ensure the woman’s continuing fertility [4].  
In Bolivia Aymara and Quecha people believe the placenta has its own spirit. It is to be 
washed and buried by the husband in a shady place. If this ritual is not performed 
correctly, the mother or the bay may become very sick or even die.  
In Dalmatia (Croatia) the placenta was buried under a rose bush, thus the child would 
always have rosy cheeks [4].  
In Indonesia the rituals vary per isle and/or tribe. Often offers such as flowers (symbol 
for good smell and fame), a piece of paper, a pencil (so that the baby will be able to 
write in future) and a needle (symbols for intelligence, smartness and wisdom) 
acompagny the placenta. The placenta is buried next to the house, on the left hand side 
if it’s a girl, on the right hand side if it’s a boy. A fence is erected around the site, 
which is lit by a lamp. In some parts of Java the placenta is set afloat, decorated with 
flowers and little lights, to be eaten by crocodiles [5]. In Bali the Balinese society is 
founded on the Hindu caste system; life on earth is only one stage in the continuity of 
existence. For this reason, the umbilical cord is preserved and kept for life, whilst the 
placenta is placed in a coconut and buried as they do in Java. On Sulawesi the Torajan 
of Tana Toraja bury the placenta in a bag of woven bamboo on the eastern side of the 
house, because east is associated with life and the rising sun. It is believed that if any 
Torajan travels far away from home, the placenta, a kind of double, will lure him/her 
back to his/her place of birth [6].  
The Maori in New Zealand bury the placenta ritually on the ancestral grounds, as well. 
Among the Indian tribes in North-America there is a belief that the soul lives in the birth 
organ; when the cord and the afterbirth have dried up and dropped away, they’re 
tenderly gathered up by the mother and arranged in a sacred fabric that she have 
woven during pregnancy. This bundle is then buried secretly, and retrieved whenever 
the tribe moves. This bundle is presented to the grown person when they appear to 
have children who will survive adulthood.  
In the Philipines mothers bury the placenta with books in hopes of a smart child. 
Burying the placenta is one of the Buddhist ceremonies of Thai (Thailand). This is 
performed to be sure good will befall in life and evil forces will be warded off. The 
placenta is preserved in an earthenware jar after it has been dried with salt, because a 
suitable site for the burial has to be determined according to a set of strict rules. The 
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burial must take place in a special site, dependent on the month and year of birth of the 
baby. For example a child born in the year of the ox and pig are best matched to the 
sugar palm, or lotus. 
The Hmong (Vietnam) word for placenta means “jacket”, as it is considered an infant’s 
first and finest clothing. The Hmong baby’s placenta is buried inside the house of its 
birth. Hmong people believe that after death the soul must retrace the journeys 
undertaken in life until is reaches the burial place of its placenta jacket. The placenta 
must be retrieved after death to ensure physical integrity in next life. 
 
 
 
CONSUMPTION OF THE PLACENTA (PLACENTOPHAGY) 
 
 
Placenta is the organ through which the foetus receives nourishment. Many cultures 
consider it rich in nutrients. It is even said to relieve, or prevent a postnatal depression.  
 
In Uganda, the Baganda refer to the placenta as a “spirit-child”. The grandparents eat 
it, so that the child’s spirit will remain in the clan. Except for the placenta of the king, 
because this is considered to posses lethal power. It is always carefully dried and 
preserved. When the old king dies, the new king is considered to own the royal power 
only upon being given the old king’s royal placenta [7].  
Consumption of the placenta by mothers is considered traditional among some 
Vietnamese and Chinese people [3]. Chinese believe a nursing mother should boil the 
placenta to make a broth (bouillon) and then drink it to improve her milk. Li Shih-chen 
recommended a mixture of milk and placental tissue for a disease known as “ch’I 
exhaustion”, an ill-defined syndrome characterized by anemia, weakness of the 
extremities and coldness of the sexual organs with involuntary ejection of semen [8]. 
The Chinese ch’I was a vital force (like the placenta in Egypt). 
Indians eat the placenta as a delicacy and a source of strength and [9]. 
Even the British cooking show “TV Dinner” had an edition on placentophagy, although 
it did not go well. After the broadcasting in 1998, the British Journal “The 
Independent” wrote: “The program showed a London couple celebrating the birth of 
their granddaughter by preparing and eating the baby’s placenta as a means of 
reflecting rituals around the world and symbolical sharing in the baby’s gene pool. They 
served it as a paté on bread. The father ate 17 portions, but the other guests were less 
enthusiastic”.   
More recently, the Dutch “Volkskrant Magazine” had an item on modern placentophagy 
[10]. The owner of a restaurant in Amsterdam (“Kantine West”) prepared a special 7-
 146
 course dinner for a couple and six friends to celebrate their newborn baby. Two of the 
courses were prepared of the placenta from this baby. The guests were surprised about 
the tastiness of these courses. Although it is not presented on the official menu to 
avoid provoking other guests who are not interested, the owner of the restaurant is 
prepared to cook a comparable dinner on request. For those who want to try to prepare 
a “placental meal” themselves, in September 1983, Mothering Magazine (USA) 
published some recipes with human placenta. You can find these recipes after the 
reference-section of this survey. 
 
 
 
HEALING POWERS  
 
 
All over the world there are people who believe(d) in a beneficial power of the placenta 
and/or its umbilical cord. 
 
In Argentina Araucan Indians dried the cord and ground it to powder to give a little to 
the child when it was sick [3].  
A comparable ritual was performed in Haiti, where the Mirebalais preserved part of the 
cord. If the child became ill the cord was boiled and the broth (bouillon) was given as a 
medicine [3].  
The people from the village of Topotzlan In Mexico used the umbilical cord as a remedy 
for eye trouble, as described in study of Robert Redfield from Chigaco 1930 and 
confirmed by Oscar Lewis in 1951 [3].  
In Peru they let an ailing infant suck on the cord [3].  
Jamaicans used the placental membranes to prevent irritation of the child by a ghost. 
Therefore the tissue was carefully parched over a hot stone and put into the infant’s 
tea. 
In the “modern” Western world special power was attributed to the placenta, as well. 
Namely, some believe placentophagy helps to prevent postnatal depression [11].  
Especially in France placental extracts were used in commercially available (facial) 
creams until 1994. From that year on, this fell into disuse, for in the united Kingdom 
the collection of placentae from unknowing mothers was forbidden. The reason for this 
was that it has  become obvious that each year 360.000 kilograms were shipped into 
France for cosmetical and pharmaceutical industries over there.  
Up to about ten years ago in many Dutch hospitals – under which our own institution – 
placentae were sold for one guilder each to the pharmaceutical industry, as well. 
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Nowadays there is a new placenta-related therapeutical goal. After birth of the child 
and clamping of the umbilical cord, foetal blood remains in the umbilical and placental 
vascular bed. This blood contains many stem cells, which can be used for a bone-
marrow transplantation [12].  
However, the placenta and placental proteins have also been associated with the origin 
of diseases. For example preeclampsia does not disappear as long as the placenta is in 
the uterus. Recently, Oura et al. [13] showed that a human placental growth factor 
(PIGF-2) is linked with an increase in inflammatory response, resulting in vascular 
enlargement, edema and inflammatory cell response.  
 
In summary, in most rituals the placenta is believed to contribute to a fortunate and 
healthy future for the child it originates from. However, no recent proof of these rituals 
was found in literature, and probably most rituals presented here are seldom, if ever, 
carried out nowadays. Nevertheless, these historical and socio-cultural perspectives on 
the human placenta emphasize the importance of this special organ for human beings 
and for human being.  
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RECIPES  
(Mothering Magazine, USA, 1983) 
 
 
placenta cocktail 
¼ cup raw placenta 
8oz V-8 juice 
2 ice cubes 
½ cup carrot 
blend at high speed for 10 seconds 
 
placenta lasagna 
Use your favorite Lasagna recipe and substitute this mixture for one layer of cheese: 
Quickly saute meat of ¾ placenta, ground or minced in 2 tablespoons (tbl) of olive oil, 
add 2 sliced cloves of garlic, ½ tsp. Oregano, and one whole tomato or 2 tbl tomato 
paste. 
 
placenta spaghetti 
Cut the meat of ¾ placenta into bite size pieces, then brown quickly in 1 tbl butter plus 
1 tbl olive oil. Then add one can of tomato puree, 2 cans crushed pear tomatoes, 1 
onion, 2 cloves of garlic, 1 teaspoon (tsp) molasses (“suikerstroop”), 1 bay leaf, 1 tbl 
rosemary, 1 tsp each of salt, honey, oregano, basil and fennel. Simmer 1½ hour. 
 
placenta stew 
Cut meat or ¾ placenta in bite size chunks, 1 potato (cubed), ¼ cup fresh parsley, 2 
carrots, 3 ribs celery, 1 zucchini, 1 large tomato, and 1 small onion. Dredge meat in 1 
tbl spoon flour mixed with 1 tsp salt, ½ tsp paprika, a pinch of cloves, pinch of pepper, 
6-8 crushed coriander seeds. Saute meat in 2 tbl oil, then add vegetables (cut cup) and 
4-5 water. Bring to full boil, then simmer for one hour. 
 
placenta pizza 
Grind placenta. Saute in 2 tbl olive oil with 4 garlic cloves, then add ¼ tbl fennel, ¼  
tsp pepper, ¼ tsp paprika, ¼ tsp salt, ½ tsp oregano, ¼ tsp thyme, and ¼ cup of 
wine. Allow to stand for 30 minutes with your favorite homemade pizza recipe.  
 
 
Additionally, my colleague (AR) suggested to start a new Dutch tradition, perhaps 
useful during a baby-shower? 
“moederkoekhappen”
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DANKWOORD
 
 
DANKWOORD 
Het leven van een promovendus wordt vaak gezien als een eenzaam bestaan. Het feit 
dat er uiteindelijk één naam op de voorkant van het boekje staat, versterkt deze 
gedachte alleen maar. Niets is echter minder waar. Ondanks tegenslagen is het me 
gelukt de overschrijding van de vier jaar die ik oorspronkelijk had te beperken. Niet in de 
laatse plaats is dit te danken aan de goede en prettige samenwerking met anderen. Een 
aantal wil ik met naam noemen. 
Op de eerste plaats natuurlijk Prof. Smits, beste Paul; 
Bedankt voor het telkens opbouwende commentaar en immer positieve instelling. Met 
name dat laatste is voor mij erg belangrijk geweest. Het is bekend dat een 
promotieonderzoek zelden zonder valkuilen, struikelblokken en andere tegenslagen 
verloopt. Maar de hindernissen op mijn weg waren soms wel buitenproportioneel van 
aard. Fijn dat er altijd een doos tissues op jouw kamer klaarstond, zodat ik me weer 
voldoende kon ontladen voor een volgende stap. 
Prof. Russel, beste Frans; 
De dag dat ik begon als arts-onderzoeker, was voor jou de eerste dag als hoogleraar. 
Het placentaonderzoek was binnen de transportgroep een beetje een buitenbeentje. Dat 
bleek zeker na de verhuizing van een deel van de afdeling naar “de toren”, waar men 
zich voornamelijk met transport in de nieren bezig houdt. Gelukkig bleef jij gemakkelijk 
bereikbaar. Wel was het voor mij merkbaar dat mijn basis totaal anders is dan de jouwe, 
want zo diep als jij in het transport zit, dat was voor mij niet altijd gemakkelijk te 
volgen. Ach, een beetje uitleg en studiewerk doet wonderen… Ook jij bedankt. 
Prof. Steegers, beste Eric; 
Jij was de eerste die met mij over onderzoek begon. Ik weet niet of ik zonder jou ooit 
aan een promotieonderzoek zou zijn begonnen. Ik ben blij dat ik het heb gedaan, ik heb 
er veel van geleerd. Midden in mijn onderzoeksjaren heb jij Nijmegen verlaten. Met 
name in het begin was dat lastig. Maar net als met jouw carrière is het ook met dit 
proefschrift goedgekomen.  
Dr. Elving, beste Lammy; 
Bedankt voor je kritische blik op het onderzoek en vooral op de manuscripten. Jouw 
adviezen hebben een grote bijdrage geleverd aan de tekst die in dit proefschrift is 
gedrukt. Bedankt ook dat je ook aandacht had voor het leven naast dat van 
onderzoeker. 
Fons Wouterse; 
De belangrijkste persoon bij het aanleren van de experimentele technieken en het leren 
kennen van de ins en outs van de opstellingen. Buiten dat kwam jij ook altijd opdraven 
op de meest idiote tijdstippen als ik weer eens met zwangerschapsverlof of iets 
dergelijks was om ervoor te zorgen dat er geen placenta van een zwangere vrouw met 
diabetes mellitus werd gemist. Jouw praktische bijdrage is denk ik wel de belangrijkste 
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geweest om ervoor te zorgen dat het onderzoek niet te veel vertraging opliep. Maar ik 
geloof dat je wel weet hoe dankbaar ik je ben. 
Jenny Copius Peereboom-Stegeman; 
Net als jij, mag ik mijzelf nu een beetje placenta-goeroe noemen. Bedankt voor het 
meedenken aan het morfologisch gedeelte van mijn studie. Bedankt dat je bereid was 
de begeleiding van Selina over te nemen tijdens mijn afwezigheid, mede namens Selina. 
Jeroen van der Laak: 
Bedankt voor het ontwikkelen van de VIDAS, het rekenwerk en de begeleiding van 
Selina, die onverwacht iets intensiever was dan tevoren was ingeschat. Zonder ook 
maar een seconde erover na te denken, ben jij samen met Selina verder gegaan. 
Geweldig! 
Leni Siero; 
Ook jij nam belangeloos een deel van het onderzoek over, omdat ik met een kind in mijn 
buik niet aan straling blootgesteld mocht worden. De experimenten die jij hebt 
voortgezet zijn van groot belang geweest voor het totstandkomen van hoofstuk 7. 
Bedankt. 
Joop Borggreven; 
Inmiddels heb jij de afdeling verlaten om van je verdiende vrije tijd te genieten. Voor je 
vertrok heb je voor mij de compliantie van de foetale vaten van de placenta bestudeerd. 
Wat was ik blij dat deze niet verschillend bleek tussen diabetespatiënten en 
controlepersonen!!! 
Jeanne Pertijs; 
Bedankt voor het prepareren van de vaten die Joop heft gebruikt in het onderzoek. Ik 
heb het later ook geprobeerd voor ander onderzoek; het is monnikenwerk. 
Yuen Tan; 
Sommigen zullen jou alleen nog maar kennen uit “verhalen over vroeger”. Voor mij was 
je belangrijk voor het opzetten en aanleren van de HPLC-methode om het 
foliumzuurgehalte in de perfusievloeistof te bepalen. Bedankt voor je eeuwige geduld 
met deze – in jouw woorden -  “kwebbeltante”. 
Jeroen van den Heuvel; 
Van jou heb ik geleerd dat er bij een Western Blot meer komt kijken dan je denkt. Ik ben 
er trots op dat ik heb bijgedragen aan jouw eerste publicatie. 
Lisanne van den Berg, Chantal Bovee, Miranda Stringer, Alexander Rennings en Peter 
Pickkers; 
Bedankt voor de gezelligheid, attentheid, eerlijkheid en alle andere dingen die je van een 
goede collega/kamergenoot mag verwachten. De omschakeling van vrouwen naar 
mannen was even groot, maar viel zeker niet tegen. 
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Alle collega arts-onderzoekers van de afdelingen Obstetrie-Gynaecologie, Epidemiologie 
en Biostatistiek en Interne Geneeskunde; 
Dit zijn er de afgelopen jaren zoveel geweest dat ik maar geen namen noem omdat ik 
bang ben iemand te vergeten. Bedankt voor de prettige samenwerking, goede nieuwe 
ideeën, de uitjes etc. Kortom, alles wat voor een arts-onderzoeker van belang is. Eva 
Maria Roes en Maarten Raaijmakers bedankt voor de goede samenwerking en prettige 
afronding van de NAC-studie in de placenta. 
Simone Dekker, Femke van de Water, Annabel Walker, Marieke Verstegen, Selina van 
der Wal en Eva Goula; 
Bijna geen enkel proefschrift komt tot stand zonder een bijdrage van studenten. Buiten 
werkelijke hulp brengt dat ook een hoop leven in de brouwerij. Daar houd ik wel van… 
Hilde Basten - Marjo Beuting - Caren Thijssing - Marja Brederveld - Margreet Centen - 
Loes van Dalen - Marloes van Dalen - Hans van Dillen - Rianne van Gaalen - Jos van 
Gent - Mariёlle Fisscher - Vera van Haaren - Irma Buis - Hester de Haas - Marijke van 
der Heijden - Inigo Heijmans - Els Hendriks - Erik Hendriks - Lena Holtman - Lilian 
Janssen - Maartje de Kat - Marlies Knuiman - Patricia Koppelman - Petri Kusters - Iris 
van Mil - Monique Hoogeveen - Moniek Raemakers - Marjolein Scheltinga - Daniēlle van 
Hove - Marja Scholten - Marij Strijbosch - Sandra Timmer - Maria Vos - Dorrit Grosfeld - 
Kim van de Water - Betty van der Weijden - Ali Wessel; 
Bedankt voor jullie hulp bij het verkrijgen van de placenta’s. 
Moeders; 
Bedankt voor het afstaan van de placenta en bloed voor dit onderzoek. 
Medewerkers van de laboratoria CKCL en ACE; 
Bedankt voor de hulp bij de benodigde bepalingen, in het bijzonder Dorine Swinkels, 
Annelies Mooren, G. van de Wiel, Fred Sweep en Tijn Seegers. 
Greet Goverde; 
Fijn dat je bereid was om het manuscript na te lezen op Engelse taal- en stijlfouten. 
Bas van Abel; 
Een zelfgebakken kaft om het proefschrift. Ik moet de eerste zijn die dat kan zeggen. Hij 
ziet er geweldig uit. 
Else en Maike; 
Omdat jullie achter mij (zijn blijven) staan. 
Mama; 
Jij was en bent nog altijd een belangrijke spil in ons gezin. Er is zoveel waarvoor ik je 
moet bedanken. Met name voor al die keren dat ik je onverwacht om hulp vroeg bij de 
opvang van de kinderen. Maar niet in de laatste plaats gewoon omdat je al ruim 33 jaar 
mijn moeder bent. 
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Amber, Mees en Jasmijn; 
Bedankt voor al die keren dat jullie mij frietjes kwamen brengen op het lab als ik weer 
eens tot diep in de nacht doorging.  
Erik; 
Mijn man, vader van mijn kinderen. Volgens mij was het af en toe flink afzien als ik het 
weer onverwacht liet afweten aan het eind van de dag. Je bent een geweldige vader 
voor onze kinderen en een fantastische man voor mij. Bedankt voor jouw 
onvoorwaardelijke steun in de afgelopen jaren. 
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Tanya Maria Bisseling werd geboren op 24 mei 1971 als oudste van vier dochters van 
Jan Bisseling en Ria Bisseling-Hermsen. In 1989 deed zij eindexamen aan het Stedelijk 
Gymnasium te Nijmegen, waarna zij aan de studie Geneeskunde aan de Katholieke 
Universiteit te Nijmegen begon. In mei 1994 behaalde zij haar doctoraalexamen, 
gevolgd door het artsexamen in maart 1997. Van april 1997 tot februari 1998 werkte 
zij als AGNIO Heelkunde in het Rijnstate Ziekenhuis te Arnhem. Vervolgens werkte zij 
als  AGNIO Obstetrie-Gynaecologie in het Elisabeth Ziekenhuis te Tilburg. In 1997 
trouwde zij met Erik Olde. Tijdens de zwangerschap van haar oudste dochter Amber 
aanvaarde zij in 1999 een baan als arts-onderzoeker op de afdeling Farmacologie-
Toxicologie. In februari 2000 begon zij onder leiding van Prof. dr. P. Smits in 
samenwerking met de afdeling Obstetrie-Gynaecologie aan het onderzoeksproject dat 
uiteindelijk heeft geleid tot dit proefschrift met de titel “Placental function in maternal 
disease; ex vivo assessment of foetoplacental vascular function and transport in 
diabetes and preeclampsia”.  Tegelijkertijd was zij als (toekomstig) co-promotor 
betrokken bij een studie naar de kwaliteit van leven van vrouwen na een behandeling 
met een Tensionfree Vaginal Tape voor stress-incontinentie. In maart 2001 en 
november 2002 werden Mees en Jasmijn geboren. Thans is zij werkzaam op de 
afdeling Interne Geneeskunde in het Ziekenhuis Bernhoven te Veghel. 
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